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Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus associated malignancy. Previous 
studies have shown that NPC is associated with specific human leukocyte antigen (HLA) 
allotypes, which function in adaptive immunity to present viral and other antigens to the 
immune system. The role of innate immunity in NPC development remains unknown. In this 
study, we investigate possible associations between innate immunity and NPC, by identifying 
killer cell immunoglobulin-like receptor (KIR) genotypes and single nucleotide 
polymorphisms (SNPs) present in Toll-like receptor (TLR) 2, TLR4, TLR7, TLR8 and TLR9 in 
a case-control study of Singaporean Chinese.  
 
KIR genotyping of the Singaporean population was carried out on the three major ethnic 
groups, Chinese, Malay and Indian, to obtain the KIR profile of the Singaporean population. 
Chinese and Malay were the most similar, and Chinese and Indian, the most dissimilar. In 
addition to the framework loci, KIR2DL1, KIR2DL3, KIR2DS4 and KIR2DP1 were present in 
most of the individuals, whilst KIR2DL2, KIR2DS2 and KIR3DL1 exhibited great variation 
across the ethnic groups. 
 
Novel HLA allelic associations with NPC were identified – HLA-Cw*0702 and B*5502 were 
protective, while Cw*1402 and B*5101 were disease-susceptible. Novel HLA haplotypic 
associations were also discovered – A*1101-Cw*0702-B*4001, which was protective, and 
Cw*1402-B*5101, which increased risk of NPC. 
 
Our results suggested that KIR3DL1 could play a possible protective role in NPC (p = 0.006; 
RR = 0.39) and this protective effect was compounded when its HLA-Bw4 ligand is absent (p 
= 0.013; RR = 0.19), suggesting that in the absence of Bw4 ligands, inhibitory KIR3DL1 is 
unable to inhibit NK cells, hence triggering increased cytolysis of EBV-infected cells, 




A trend of increasing risk with increasing number of activating KIRs was also observed and 
this was statistically significant when at least six activating KIRs were present (p = 0.020; RR 
= 2.87). Contrastingly, there was no clear trend observed for increasing number of inhibitory 
KIRs. This hinted that activating KIRs might activate NK cells and trigger non-specific 
inflammatory responses, which increases an individual’s risk for NPC.  
 
On the whole, activating KIRs were associated with increased risk and inhibitory KIRs were 
associated with decreased risk, but these results did not reach statistical significance. Further 
investigations are required to validate these findings and it is possible that both mechanisms 
are at work in NPC pathogenesis.  
 
No significant associations were discovered between TLR2, TLR4, TLR7, TLR8 and TLR9 
exonic SNPs and NPC. A total of nine informative SNPs were identified in TLR2, TLR8 and 
TLR9, all of which are synonymous SNPs, where there are no amino acid changes, suggesting 
the importance of the amino acid sequences of TLRs in determining ligand affinity and 
indirectly how the host responds to pathogens. Perhaps disease-associated SNPs could exist in 
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1.1 Nasopharyngeal Carcinoma 
1.1.1 Epidemiology of NPC 
Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous cell carcinoma that 
occurs in the epithelial lining of the nasopharynx (Wei and Sham, 2005). Three 
histopathological types are recognized by the World Health Organization (WHO) 
classifications (Shanmugaratnam and Sobin, 1993): Type I, squamous cell carcinoma with 
varying degrees of differentiation; Type II, non-keratinizing carcinoma; and Type III, 
undifferentiated carcinoma. In North America, a region of low NPC incidence, around 25% of 
tumor patients have type I histology; 12%, type II; and 63%, type III; conversely, in southern 
China, a high-risk region, the distributions are 2%, 3% and 95% respectively for types I, II 
and III (Wei and Sham, 2005). 
 
80 000 new cases of NPC were recorded worldwide in 2002, accounting for 0.7% of all 
cancers (Parkin et al., 2005). NPC shows evident geographical and ethnic restrictions [Figure 
1.1]. Though rare throughout most of the world with age-standardized
 
incidence rates less 
than 1 per 100 000 person-years, NPC is endemic in populations living in or originating from 
southern China, with incidence rates up to 21.4 per 100 000 person-years in males in Hong 
Kong (Chang and Adami, 2006), and in populations
 
elsewhere in China, Southeast Asia, 
Northeast India, North Africa
 
and Inuits (Eskimos) of Canada and Alaska, all of whom have
 
moderately elevated rates. Independent of ethnicity, the incidence ratios in males are 







Figure 1.1 Geographical Distribution of NPC Incidence Rates (per 100 000 person-
years) for Male Patients. [From Busson et al., 2004.]  
 
In most populations, NPC risk rises with increasing age. However, in moderate
 
risk 
populations (most notably in North Africa), an extra
 
peak in incidence occurs in adolescence 
(Parkin et al., 2005) whilst in high-risk groups, the incidence peaks around ages 50 – 59 years 
and declines thereafter (Chang and Adami, 2006). Nonetheless, in some North American 
populations and the Mediterranean region, a bimodal age distribution for NPC is observed, 
with an early peak of incidence at 10 – 20 years and a second at 40 – 60 years (Ayan et al., 
2003). 
 
NPCs are fast growing tumors with high sensitivities to radiotherapy and chemotherapy at the 
initial stage of treatment. Unfortunately, remissions are generally of short duration. With the 
exception of small tumors (less than 2 cm), the prognosis is very poor, with a survival rate 
below 50% at five years, hence better diagnostic methods and novel targeted therapeutic 




1.1.2 Etiology of NPC 
The etiology of NPC remains obscure and the mechanism of NPC tumorigenesis is complex, 
involving multiple pathways that inhibit apoptosis, promote cell proliferation or enable tumor 
cell invasions (Chou et al., 2008). Notwithstanding, NPC is known to be a multi-factorial 
disease, where various factors interact synergistically in the pathogenesis. Such factors 
include environmental, virological and genetic factors, which were proposed to explain the 
marked ethnic clustering of NPC in southern Chinese. 
 
1.1.2.1 Environmental and Dietary Factors 
A variety of possible environmental and dietary factors have been extensively reviewed by 
Chang and Adami (Chang and Adami, 2006). They include cigarette smoking and 
occupational exposures to fumes, smokes, dusts or chemicals (increased risk by two- to six-
fold), or the consumption of salt-preserved fish (increased risk of 1.8 – 7.5), a traditional 
staple in several NPC-endemic areas, which contains high levels of nitrosamines. 
Contrastingly, frequent consumption of fresh fruits and/or vegetables, especially during 
childhood, has been associated with a lower NPC risk. The apparent protective effect of fruits 
and vegetables may be attributed to antioxidant effects, prevention of nitrosamine formation 
and other anti-carcinogenic properties. Certain chemicals, such as 12-O-tetradecanoyl-
phorbol-13-acetate found in croton and other similar plants, are potent activators of Epstein-
Barr virus (EBV) and such plants can be found in areas of high incidences (Chan, 1990).  
 
However it is difficult to prove that a particular environmental or dietary factor played a part 
in NPC pathogenesis in retrospective case-control studies. 
 
1.1.2.2 Epstein-Barr Virus 
EBV was the first human virus to be directly implicated in carcinogenesis and it was 
classified as a group I carcinogen by the International Agency for Research on Cancer 




gamma herpes virus of the Lymphocryptovirus genus, EBV infects more than 90% of the 
human population and establishes a lifelong dormant infection in the host. It has been 
implicated in the pathogenesis of several malignancies, primarily of lymphoid and epithelial 
cell origin, including Burkitt’s lymphoma, Hodgkin’s disease, non-Hodgkin’s lymphoma, 
NPC and leiomyosarcomas arising in immunocompromised individuals. 
 
Two subtypes of EBV are known to infect humans: EBV-1 and EBV-2. They differ in the 
organization of genes that code for the EBV nuclear antigens (EBNA-2, EBNA-3a, EBNA-3b 
and EBNA-3c) (Sample et al., 1990). EBV-1 and EBV-2 also diverge in geographic 
distributions – EBV-1 is observed more frequently in most populations, while EBV-2 is 
nearly as prevalent as EBV-1 in New Guinea and equatorial Africa (Sixbey et al., 1989; 
Young et al., 1987). It has been shown that nearly half of all African Burkitt’s lymphoma 
tumors carry EBV-2. In contrast, 85% of NPC tumors in Taiwan contain EBV-2 (Shu et al., 
1992). 
 
In most underdeveloped countries, primary EBV infection usually occurs early in life, 
followed by lifelong virus persistence and remains asymptomatic. In more developed regions, 
primary EBV infection could be delayed until late adolescence or adulthood and infectious 
mononucleosis results. In Singapore, EBV infection occurs early in life, with over 90% of the 
population becoming infected by the age of 10 years (Chan, 1990). Seroprevalence studies in 
the early 1970s and 1990s showed that EBV infection has not changed in the last two decades 
despite changes in other viral infections over this period (Chan et al., 1998).  
 
Transmission of EBV occurs through salivary contact. EBV preferentially infects B 
lymphocytes through the binding of the major viral envelope glycoprotein gp350 to the 
Component 3d (C3d) complement receptor, cluster of differentiation 21 (CD21), on the 
surface of B cells (Nemerow et al., 1987) and through the binding of a second glycoprotein to 




2002), inducing continuous proliferation of the infected cells. Like all herpes viruses, EBV-
infected B-cells can express four different programs of gene usage depending on the location 
and state of differentiation of the infected B cell, namely latency I – III and lytic replication. 
Latency helps in the long-term maintenance of the virus in the host while lytic replication 
effects virus production and spread. In most asymptomatic carriers of EBV, the virus is 
periodically replicated via lytic replication and infectious virions can be recovered in oral 
secretions. Activation of the lytic program appears to occur in memory B cells recirculating 
through the lymphoid tissue associated with the oropharyngeal mucosa (Faulkner et al., 2000).  
 
The initial link between EBV infection and NPC was uncovered in studies characterizing the 
antibody responses to EBV that showed NPC patients had elevated immunoglobulin (Ig) G 
and IgA antibody titers to EBV proteins expressed during replication, EBV viral capsid 
antigen (VCA) and early antigen (EA) (Henle and Henle, 1976). These titers correlated with 
tumor burden, remission and recurrence and were shown to precede tumor development by 1 
– 2 years. Such induction of IgA antibodies suggests reactivation of replication of EBV at the 
mucosal surface precedes NPC progression (Raab-Traub, 2002).  
 
Though absent in normal epithelial cells of the nasopharynx, EBV
 
is present in all NPC tumor 
cells and even in dysplastic precursor
 
lesions. An important risk factor of NPC is the dose-
response relationship that exists between EBV antibodies and NPC risk. Therefore levels of 
specific VCA-IgA and EA-IgA can be used to diagnose NPC as they indicate possible 




1.1.3 Genetic Associations of NPC  
The findings of migrant studies, case-control studies of specific markers and familial 
aggregations of the disease favor a genetic component to NPC pathogenesis. 
 
1.1.3.1 HLA Associations with NPC  
Specific HLA class I allotypes have been extensively studied in NPC. A possible association 
between HLA and NPC was first identified in Singapore. Two different HLA haplotypes were 
associated with newly diagnosed NPC, A*0207-Cw*0102-B*4601 (haplotype A2B46) and 
A*3303-Cw*0302-B*5801-DRB1*0301 (haplotype A33B58) (Chan, 1990; Chan et al., 
1983). Haplotype A2B46 had a relative risk of 3.4 and haplotype A33B58 had a relative risk 
of 2.2 (Chan, 1990). There was a consistent negative association with the alleles A*11 and 
B*13 (Chan, 1990).  
 
A meta-analysis, which combined the results of thirteen HLA association studies in southern 
China in an attempt to overcome the problem of reduced statistical power in studies with 
small sample sizes, reported positive associations of NPC with the alleles A*02, B*14 and 
B*46, and negative associations with the alleles A*11, B*13 and B*22 (Goldsmith et al., 
2002). The associations between HLA class II allotypes and NPC are less well-characterized, 
other than the extended A33B58 haplotype, A*3303-B*5801-DRB1*0301-DQB1*0201/2-
DPB1*0401 (Hildesheim et al., 2002).  
  
The role of HLA in NPC remains unclear. One hypothesis proposes that foreign antigens are 
inappropriately presented by the HLA molecules (Chan, 1990). HLA molecules bind and 
present foreign antigens to lymphocytes, so that an immune response can be mounted against 
them. Certain HLA molecules have reduced efficiencies in activating host immune responses 





Another hypothesis states that NPC disease susceptible genes may be located on chromosome 
6, within or near the HLA loci (Chan, 1990). This hypothesis was supported by a linkage 
study on sib pairs of patients in 30 families, which postulated the existence of a gene closely 
linked to the HLA loci that conferred a 21-fold increased risk of NPC (Lu et al., 1990).  
 
1.1.3.2 Other Genetic Associations of NPC 
Several genetic polymorphisms, chromosomal abnormalities and epigenetic changes have 
been identified by epidemiological studies searching for NPC susceptibility loci. 
 
Cytochrome P450 2E1 (CYP2E1) is known to activate nitrosamines and related carcinogens. 
The variant form of CYP2E1 (c2 allele) was found to be in strong association with increased 
NPC risk in Chinese (Hildesheim et al., 1997; Hildesheim et al., 1995). Glutathione S-
transferase M1 (GSTM1) plays an important role in the detoxification of several carcinogens 
in tobacco smoke. A GSTM1 null genotype was associated with an almost two-fold increase 
in risk for NPC (Nazar-Stewart et al., 1999). The human homolog of the yeast OGG1 gene 
(hOGG1) and X-ray repair cross-complementing group 1 (XRCC1) genes are involved in 
DNA repair. Subjects with putative high-risk genotypes for hOGG1, XRCC1 and CYP2E1 
had an odds ratio (OR) of 25 (Billadeau et al., 2003; Zhang et al., 2007). Polymeric 
immunoglobulin receptor (PIGR) is a cell surface receptor proposed to mediate EBV entry 
into the nasal epithelium (Norderhaug et al., 1999). A missense mutation at base pairs 1739 
was associated with an increased OR of 2.71 (Hirunsatit et al., 2003), perhaps due to a change 
in the efficiency of PIGR to release the IgA-EBV complex, resulting in EBV infection. 
 
Linkage analyses of Chinese NPC pedigrees using highly polymorphic microsatellite markers 
further identified two susceptibility loci on chromosomes 4p15.1-q12 and 3p21.31-21.2 (Feng 
et al., 2002; Xiong et al., 2004). Cytogenetic investigations identified loss of heterozygosity 
on chromosomes 3p (75%), 9p (87%), 9q, 11q, 13q, 14q and 16q (Mutirangura et al., 1997). 




appears to be critical as deletions of these regions were detected in almost all NPC samples 
(Lo et al., 2000). Recurrent chromosomal gains on chromosome 12 were frequent too (Lo and 
Huang, 2002). In addition, tumor-suppressor genes such as Ras association domain family 1A 
(RASSF1A), p14, p16 and immunoglobulin superfamily 4 (IGSF4) were found to be defective 
due to deletion or promoter hypermethylation (Chang and Adami, 2006; Lo et al., 2004). 
 
NPC association studies with killer cell immunoglobulin-like receptors (KIRs) and Toll-like 




1.2 Natural Killer Cells  
1.2.1 Innate Immunity 
Immunity in vertebrates can be classified into innate and adaptive immunity. Adaptive 
immunity is unique to vertebrates and its receptors are generated by somatic mechanisms 
such as gene rearrangements and hyper mutations during the ontogeny of each individual 
organism, generating a diverse repertoire of antigen receptors with random specificities 
clonally distributed on B and T cells. Conversely, the innate immune system is evolutionally 
conserved and is the front line of the host defensive mechanisms against invading microbial 
pathogens. It consists of germline-encoded receptors for the recognition of pathogens, with 
considerable specificity and is capable of discriminating between pathogens and self. In 
addition, the activation of the innate immune response can be a prerequisite for the triggering 
of adaptive immunity. 
 
Innate immune recognition is based on the premise that molecular structures that are essential 
for the survival of the microbes are not subject to variability, for instance lipid A of 
lipopolysaccharide (LPS). Thus the targets or recognition are molecular patterns known as 
pathogen-associated molecular patterns (PAMPs) rather than specific structures. Some 
receptors recognize PAMPs directly, while others recognize the products generated by PAMP 
recognition.  
 
1.2.2 Background of NK Cells 
Between 1974 and 1977, a series of papers from Cantor, Wigzell, Playfair and others 
described a novel lymphocyte effector function mediated by cells that were granulocytic 
lymphocytes, yet were neither B nor T cells and did not use related families of antigen 
receptors (Glimcher et al., 1977; Greenberg and Playfair, 1974; Kiessling et al., 1975). 
Termed ‘natural killer’ (NK) cells, the criteria for inducing cytotoxicity by this population 




was detected in the absence of prior immunization, compared to the exquisite rules governing 
cytotoxic T lymphocyte (CTL) killing.  
 
NK cells are bone-marrow derived lymphocytes that were originally categorized by their 
large granular morphology and their ability to lyse a variety of tumor targets and infected 
cells (Trinchieri, 1989). In addition, NK cells can secrete potent levels of cytokines, 
especially interferon-gamma (IFN-#) and tumor necrosis factor-alpha (TNF-$), and 
chemokines such as chemokine (C-C motif) ligand (CCL) 3, CCL4 and CCL5 (Biron et al., 
1999). An important component of the innate immune system, NK cells are instrumental in 
the defense against intracellular bacteria (Unanue, 1997) and parasites (Scharton-Kersten and 
Sher, 1997), and are critical for controlling several types of viral infection (Biron et al., 1989; 
Biron et al., 1999).  
 
1.2.3 NK Cell Receptors and Ligands 
NK cell activation and killing is a highly complex system of diverse inhibitory and 
stimulatory receptor-ligand interactions. Key families of NK cell receptors include the KIRs, 
Ly49 and CD94:NKG2 receptors. Identified inhibitory receptors are specific for major 
histocompatibility complex (MHC) class I ligands, while stimulatory receptors are either 
specific for upregulated ligands on both tumor and stressed cells, or ligands on normal cells.  
 
1.2.3.1 Recognition of Transformed Host Cells 
HLA molecules trigger adaptive immune responses by presenting peptide fragments to 
immune effector cells – HLA class I molecules are usually associated with presentation of 
endogenous peptides such as those from viruses, while class II molecules are specialized for 
presenting exogenous peptides encountered in endosome-related vesicles. At the cell surface, 
loaded class I molecules generally interact with T cell receptors (TCRs) on CTLs, which kill 
the presenting cell if the peptide is considered foreign (Campbell and Trowsdale, 1993). 




(Klein and Sato, 2000). Though NK cells do not have the specialized gene rearrangement 
machinery of T and B cell antigen receptors responsible for their wide repertoire (Murphy et 
al., 1987), they exhibit a clear capacity to discriminate target cells. NK cells direct their 
efforts towards infected or transformed host cells (i.e. altered self). Involvement of MHC 
class I molecules in NK cell recognition of self versus non-self was originally proposed by 
Kärre and colleagues (Kärre et al., 1986). 
 
The ‘missing self’ hypothesis (Ljunggren and Kärre, 1990) states that NK cells ignore 
potential targets expressing normal levels of autologous class I molecules and attack cells that 
do not. In the event of intracellular infection, MHC class I expression and antigen 
presentation to CTLs are sabotaged by the pathogen, resulting in reduced cell-surface 
expression of MHC class I molecules, rendering cells resistant to cytolysis by CTLs. 
However, aberrant levels of class I expression can result in spontaneous destruction by NK 
cells, as proposed by the ‘missing self’ hypothesis. It is currently accepted that NK cell 
cytotoxicity is controlled by the equilibrium between stimulatory and inhibitory signals 
mediated by corresponding NK cell receptors. Thus a contemporary form of the ‘missing self’ 
hypothesis suggests that NK cells not only patrol for abnormal cells that lack MHC class I, 
but also for those that overexpress ligands for activating receptors (Lanier, 2005). 
 
Two main classes of inhibitory receptors have been identified on NK cells in humans – the 
CD94:NKG2A heterodimers and KIRs (Raulet et al., 2001). While CD94:NKG2A 
heterodimers ignore the diversity of MHC class I and recognize a sequence element 
conserved in the signal peptide of most MHC class I molecules, KIRs embrace the diversity 
of MHC class I through direct recognition of the polymorphic determinants. As a result, a 
highly variable and polymorphic KIR system with comparable diversity as that of MHC class 





Activating receptors can be broadly classified into those that recognize MHC class I-like 
ligands and those that do not. The former group includes members of the KIR and NKG2 
families too while the latter comprises of natural cytotoxicity receptors (NCRs), natural killer 
p30-related protein (NKp30), NKp44, and NKp46, which are the most important activating 
receptors for recognition of infected cells. Ligands for NCRs are not well defined but possible 
candidates are heparan sulfate proteoglycans (HSPG) or viral ligands such as influenza virus 
hemagglutinin and hemagglutinin-neuraminidase (Biassoni, 2009). Of interest are the KIRs, 
which will be discussed further in section 1.3. The same NK cell often does not express 
stimulatory and inhibitory receptors of the same MHC class I-specificity due to overlapping 
expressions of class-I specific stimulatory and inhibitory receptors (Raulet et al., 2001). In 
general, class I-specific activating receptors tend to recognize their class I ligands with lower 
affinity than do their inhibitory counterparts (Vales-Gomez et al., 1998a; Vales-Gomez et al., 
1998b).  
 
1.2.3.2 Recognition of Pathogens 
NK cells, being a major component of innate immunity, are able to respond quickly and 
effectively to pathogens. It was previously thought that NK cells were indirectly activated by 
antigen-presenting cells (APCs) – PAMPs from the pathogens acted on dendritic cells and 
macrophages, triggering cytokine production and the cell-cell contact elicited responses from 
NK cells (Colucci et al., 2002; Walzer et al., 2005). Currently, the association between NK 
cells and APCs is well-characterized, where both cell populations act upon each other, 
inducing production of cytokines, proliferation and maturation (Andoniou et al., 2005; 
Watford et al., 2004; Zanoni et al., 2005). Recent evidence as reviewed by Lauzon et al. 
(Lauzon et al., 2007) suggests that NK cells express a variety of TLRs, or at least express 
mRNA for all currently known TLRs, albeit at varying levels, and appear to be able to 
respond to TLR ligands directly even in the absence of activated accessory cells. TLRs will 




1.3 Killer Cell Immunoglobulin-Like Receptors 
The discovery of KIRs conferred an additional function to the HLA class I molecules encoded 
by genes within the MHC locus on chromosome 6p22. Through their interactions with 
specific KIR isotypes that inhibit NK cell activity, certain MHC class I molecules are now 
known to protect healthy cells from NK cell-mediated cytolysis. Other KIR isotypes, on the 
other hand, stimulate the activity of NK cells. 
 
1.3.1 Genetic Organization of KIR 
The KIR locus comprises of fifteen genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, 
KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, 
KIR3DL2, KIR3DL3 and KIR3DS1) and two pseudogenes (KIR2DP1 and KIR3DP1) 
(Trowsdale, 2001) clustered tightly in approximately 150 kb of chromosome 19q13.4 within 
the 1 Mb leukocyte receptor complex (LRC). KIR genes are situated within a segment of 
DNA that has undergone substantial expansion and contraction over time and inspection of 
KIR haplotypes suggests a history of gene duplication and unequal crossing over in the region.  
 
1.3.2 Structure of KIR 
KIR nomenclature is based on two features: (i) the number of extracellular Ig-like domains 
(D0, D1, D2); (ii) the length of the cytoplasmic domain. ‘2D’ indicates two Ig-like domains 
(D0/D2 or D1/D2) and ‘3D’, three Ig-like domains (D0/D1/D2). ‘L’ designates a long 
cytoplasmic domain, and ‘S’, a short domain; while ‘P’ denotes putative pseudogenes. 
 
On the whole, KIR genes are comprised of a nine-exon unit, which is representative of the 
organization of the ancestral gene. Exons 1 and 2 encode for the signal peptide and the first 
two amino acids of the mature polypeptide; exons 3, 4 and 5 each encode an Ig-like domain, 
named D0, D1 and D2 respectively; a stem, encoded by exon 6, connects the D2 domain to 
the transmembrane domain, which is encoded by exon 7; the cytoplasmic tail is encoded by 




KIR3DL and KIR2DL genes are inhibitory due to the presence of a full-length cytoplasmic 
domain with two immunoreceptor tyrosine-based inhibition-motifs (ITIMs). Conversely, the 
activating natures of KIR2DS and KIR3DS genes are attributed to the presence of a positively 
charged lysine residue within the transmembrane region, which is able to recruit DAP12 
(DNAX activation protein of 12 kDa), an adaptor molecule containing immunoreceptor 
tyrosine-based activation motifs (ITAMs). KIR2DL4 is the exception, as it has a positively 
charged arginine residue in its transmembrane region and appears to transduce activating 
signals (Kikuchi-Maki et al., 2003) through its interactions with Fc"RI# (Fc epsilon receptor 
type I gamma chain) (Kikuchi-Maki et al., 2005) in spite of its long cytoplasmic tail and a 
single ITIM motif. Two pseudogenes, KIR2DP1 and KIR3DP1, have been identified. 
KIR2DP1 shares high sequence similarity with KIR2D genes, and KIR3DP1, which resembles 
KIR3DL3 in parts of the gene, may represent an ancestral KIR gene. 
 
1.3.3 KIR Ligands  
KIRs are expressed by classical NK and subpopulations of T cells. With the exception of null 
alleles and possibly KIR3DL3, all known KIRs in a given individual’s KIR gene repertoire are 
expressed, albeit in an apparently stochastic manner, to generate a large number of different 
and overlapping subsets of KIR expression patterns (Raulet et al., 2001). Ligands for several 
KIRs have been demonstrated to be subsets of MHC class I molecules.  
 
Inhibitory KIRs recognize ubiquitously distributed MHC class I molecules; activating KIRs 
might bind the same ligands but with reduced affinities, or different ligands entirely. Studies 
have shown the binding affinities of inhibitory KIRs are dependent on the peptides of the 
MHC class I complexes (Rajagopalan and Long, 1997; Zappacosta et al., 1997). The same 
might hold true for activating KIRs too. 
 
Dimorphisms in the HLA-Cw $1 domain, characterized by Ser77/Asn80 and Asn77/Lys80, 




KIR2DS1 interact with C2, while KIR2DL2, KIR2DL3 and KIR2DS2 interact with the 
alternative C1. KIR3DL1 interacts with HLA-B allotypes with the serologically-defined motif, 
Bw4, distinguished by Leu82/Arg83. KIR3DL2 interacts with some HLA-A allotypes, A*03 
and A*11. No KIR has yet been shown to bind allotypes containing Bw6, the alternative to 
Bw4 positive allotypes. KIR2DL4 probably interacts with HLA-G. A summary of KIR 
isotypes and their specificities are shown in Table 1.1.  
 
Table 1.1 Structures and Ligands of KIRs.  [Adapted from Rajagopalan and Long, 2005.] 
 
 
KIR2DS1 and KIR2DS2 molecules bind to HLA-Cw with lower affinities than their KIR2DL 
inhibitory counterparts (Biassoni et al., 1997; Winter et al., 1998). Such a difference may be 
essential to ensure that inhibitory signals override activating signals. Inhibitory receptors 
serve an important function of blocking many potential NK responses to protect normal cells 
from being killed and to limit the production of pro-inflammatory cytokines such as IFN-# 
and TNF-$. By blocking activation signals at a very early point, these MHC class I-specific 





In summary, the KIR family of molecules appears to be biased towards recognition of HLA-
Cw and HLA-Bw4 allotypes, indicating that the KIR repertoire is not all-inclusive for human 
MHC class I allotypes. 
 
1.3.4 KIR Signaling 
Most inhibitory KIRs have two ITIMs, which operate in tandem to mediate inhibition. ITIM 
phosphorylation results in recruitment of SHP-1 (Src-homology domain-bearing tyrosine 
phosphatase) to specifically inhibit the proteins involved in the intracellular activation 
cascade (Raulet et al., 2001). Activating KIRs associate with the ITAM-bearing adaptor 
molecule, DAP12, via the positively charged lysine residue in the transmembrane region. 
Upon ligation of activating KIRs, DAP12 is phosphorylated and ZAP-70/Syk kinase is 
recruited, triggering an intracellular signaling cascade. In addition, ligation of activating KIRs 
may modulate the response by inducing the apoptosis of mature cytotoxic cells. 
 
1.3.5 KIR Haplotypes  
The order of the KIR genes along the chromosome has been determined for two distinct 
haplotypes [Figure 1.2], providing a framework for their genomic order (Wende et al., 1999; 
Wilson et al., 2000). The genes are organized in a head-to-tail fashion, where each gene is 
roughly 10 – 16 kb in length, separated by 2 kb sequences, except for a 14 kb unique 
sequence upstream of KIR2DL4. Three well-conserved regions exist at both ends of the 


































































Present on virtually all haplotypes, KIR3DL3, KIR3DP1, KIR2DL4 and KIR3DL2 are referred 
to as framework loci. Haplotypes have been classified into two primary groups, A and B, 
based on their gene contents. Originally differentiated by the presence of a 24 kb HindIII 
fragment (present on group B haplotypes and later correlated to the presence of the KIR2DL5 
gene) on Southern blot analysis (Uhrberg et al., 1997), these haplotype groups are currently 
distinguished by the activating and inhibitory KIR genes present. According to the latest KIR 
haplotype group definition, group B haplotypes possess different combinations of KIR2DL5, 
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1 genes, whereas group A haplotypes 
possess a single activating gene, KIR2DS4, as well as four inhibitory genes encoding proteins 
representing the main MHC class I specificities, KIR2DL1, KIR2DL3, KIR3DL1 and 
KIR3DL2 (Marsh et al., 2003). Group B haplotypes display greater variability in the number 
of genes present, possessing between one and five activating KIRs (i.e. KIR2DS1, KIR2DS2, 
KIR2DS3, KIR2DS5 and KIR3DS1) and may incorporate inhibitory KIR genes that are known 
to be absent in group A haplotypes (i.e. KIR2DL2 and KIR2DL5) (Uhrberg et al., 2002).  
 
While approximately equally distributed in Caucasians (Hsu et al., 2002a; Uhrberg et al., 
1997), group A haplotypes are more frequent in Japanese (76.8%), Han Chinese (74.7%) and 
Koreans (73.4%) (Jiang et al., 2005; Whang et al., 2005; Yawata et al., 2002b). In contrast, 
Australian Aborigines have a low frequency of group A haplotypes of only 13% (Toneva et 
al., 2001). Overall, diversity in haplotype structure has given rise to more than a hundred 
individual KIR profiles observed across various populations (Yawata et al., 2002a). Such 
extreme divergence in haplotypic frequencies between human populations could indicate 
regional population differences in pathogen-driven selection (Parham, 2005). 
 
1.3.6 KIR Diversity 
The KIR gene locus displays extensive diversity (Uhrberg et al., 1997), which stems from 
both allelic polymorphisms of KIR genes and variability in the number and types of genes 




individuals will have the same KIR genotype (Shilling et al., 2002a). Differential clonal KIR 
gene expression patterns (Valiante et al., 1997) adds yet another layer of complexity. Perhaps 
such diversity has its origins in selection pressures, similar to those proposed for HLA loci. It 
is noteworthy that certain combinations of fetal HLA-Cw allotypes with maternal KIR 
predispose to pre-eclampsia (Hiby et al., 2004) and  an excess of inhibitory KIRs could be 
associated with spontaneous abortion (Varla-Leftherioti et al., 2005; Varla-Leftherioti et al., 
2003). Such associations could be the major forces driving KIR/HLA polymorphisms. KIR 
has been found to play a greater role than HLA in determining the expressed NK cell 
repertoire (Shilling et al., 2002b).  
 
It is doubtful that having more KIR genes confers a strong evolutionary advantage in the long 
term, since haplotypes bearing fewer KIR genes are as frequent as those with a higher number 
(Uhrberg et al., 1997). However differences in numbers and qualities of KIR genes could 
influence the NK cell-mediated immune response. Since HLA ligands and KIRs are encoded 
by different chromosomes, KIRs could be expressed without the corresponding expression of 
HLA ligands. Thus individuals without any functional inhibitory KIR/HLA pair would have 
to rely solely on the CD94:NKG2A inhibitory receptors for HLA ligands. But it is possible 
that NK cells of such individuals would be less capable of defending against pathogens 
inducing selective downregulation of certain HLA molecules, or that the use of different 
receptors confers qualitative differences to their responses against pathogens.  
 
Expansion and contraction of the KIR region appears to have occurred due in part to unequal 
crossing over. One consequence of such molecular genetic events is the possible generation of 
KIR haplotypes with two (or more) copies of a gene on a single haplotype and rearrangement 
of gene order. Since most KIR typing methods are designed to determine presence or absence 
of genes and subtyping of individual KIR genes in families has been performed in only a 
limited number of studies, haplotypes containing multiple copies of the same gene would 




been observed for most of the KIR genes, with a total of 292 alleles reported for the 16 KIR 
genes in January 2008, with KIR3DL3 as the most polymorphic with 55 alleles; and KIR2DL2 
and KIR2DP1, the least polymorphic with 5 alleles (Robinson et al., 2005).  
 
1.3.7 KIR Disease Associations 
KIRs are likely to play a significant role in the control of the immune response, which would 
explain the associations observed between certain KIR genes in rheumatoid arthritis, psoriatic 
arthritis and control of HIV disease progression. Table 1.2 summarizes some KIR disease 
associations.  
 












1.4 Toll-Like Receptors  
The mammalian innate immune system serves as the first line of defense against any 
infections, in which TLRs play a key role. Originally identified in vertebrates as homologues 
to the Drosophila melanogaster Toll protein, TLRs are membrane proteins that recognize 
PAMPs found in molecules broadly expressed by different groups of micro-organisms and 
trigger innate immune responses via various signaling pathways. Consistent with their role in 
pathogen recognition, TLRs are expressed by the main sentinel cells of innate immunity, such 
as epithelial cells, neutrophils, macrophages and dendritic cells. TLR2 and TLR4, the major 
receptors for bacterial lipoproteins and LPS respectively, are also expressed on B and T cells 
which mediate the more complex adaptive immunity via a large repertoire of antigen-specific 
immunoglobulin-class receptors (Imler and Hoffmann, 2001).  
 
Given that NK cells play an important role in the early innate immune response to pathogens 
and the fact that they lack cognate receptors for the generation of specific adaptive immune 
responses, it is attractive to speculate that NK cells express TLRs allowing them to directly 
recognize pathogen-derived products and these would function in the early sensing of 
infection. Indeed this has proved to be the case and reports are beginning to emerge, detailing 
a role for TLR2 (Becker et al., 2003), TLR3 (Pisegna et al., 2004; Schmidt et al., 2004; Sivori 
et al., 2004), TLR9 (Sivori et al., 2004) and more recently, TLR7 (Hart et al., 2005) and 
TLR8 (Hart et al., 2005) in NK cell biology. TLR4 is expressed on the surface of human NK 
cells (O'Connor et al., 2006). Although NK cells express virtually all TLRs, not all are 
inherently functional and indirect activation of NK cells by TLR ligands on accessory cells is 
likely to play a significant role in the NK cell response to microbial pathogens.  
 
To date, there are thirteen identified mammalian TLRs, of which eleven are expressed in 




1.4.1 Genetic Organization of TLRs  
TLR genes are dispersed throughout the genome: TLR1, TLR6 and TLR10 genes are located 
on chromosome 4p14; TLR2 and TLR3 map to chromosome 4q31.3–35; TLR4 resides on 
chromosome 9q32–33; TLR5 is at chromosome 1q33.3–42; TLR7 and TLR8 are located as a 
tandem on chromosome Xp22; and TLR9 maps to chromosome 3p21.3 (Akira et al., 2001). 
 
1.4.2 Structure of TLRs  
Characterized by an extracellular amino terminus, TLRs are type I transmembrane 
glycoproteins with an amino-terminal leucine-rich repeat (LRR) domain and a carboxyl-
terminal intracellular tail containing a conserved region of approximately 200 amino acids, 
the Toll/interleukin-1 receptor (TIR) homology domain. TIR domain mediates protein-protein 
interactions between TLRs and the signal-transduction components and is the defining motif 
of the TLR/ interleukin-1 (IL-1) receptor superfamily, which includes the receptors for the 
cytokines, IL-1 and IL-18, and is likely to be one of the earliest signaling domains to have 
evolved (Kimbrell and Beutler, 2001). Although the IL-1 receptor and TLRs have very 
different extracellular domains, their TIR domains allow both receptor types to activate 
similar signal-transduction pathways. 
 
1.4.3 TLR Ligands 
TLRs can be clustered into two broad groups – TLRs that respond to bacterial stimuli (TLR1, 
TLR2, TLR4, TLR5, TLR6 and TLR11) and TLRs that recognize nucleic acid derivatives or 
small molecules with structural similarities to purine nucleotides (TLR3, TLR7, TLR8 and 
TLR9) (Gay and Gangloff, 2008). Unlike other TLRs, the latter group localizes not to the cell 
surface, but to intracellular compartments, primarily the endoplasmic reticulum but also 
acidified compartments, the late endosome and lysosome. 
 
Bacterial stimuli include endogenous and exogenous protein ligands such as flagellin (TLR5) 




membrane of Gram-negative bacteria, (TLR4) (Poltorak et al., 1998) and lipoteichoic acid, a 
lipid from the cytoplasmic membrane of Gram-positive bacteria, (TLR2). TLR2 has been 
shown to form heterodimers with either TLR1 or TLR6, which discriminates between triacyl 
and diacyl lipopeptides (Kawai and Akira, 2006) respectively, but other TLRs are believed to 
form homodimers (Saitoh et al., 2004).  
 
Nucleic acid-like molecules refer to non-self nucleic acids derived from bacteria and viruses. 
TLR9 responds to DNA containing unmethylated CpG dinucleotides; TLR7 and TLR8 are 
activated by GU-rich single-stranded RNA and TLR3 by double-stranded RNA. A group of 
small synthetic drug molecules can also stimulate TLR7 and TLR8 and other molecules 
chemically similar to guanosine nucleotides are also effective agonists of TLR7 and TLR8. 
 
 
Figure 1.3 TLR Ligands. [From Kawai and Akira, 2006.] 
 
1.4.4 TLR Signaling 
Evidence suggests that the basic mechanism of signal transduction in TLRs is ligand-induced 
dimerization (Gay et al., 2006). This extracellular crosslinking is transmitted across the 
membrane and causes rearrangement of the cytoplasmic domain, which in turn generates 
downstream signaling. Unlike other type I receptors, activated TLRs do not have enzymatic 
activities. Instead, the rearranged TIRs act as a scaffold for the recruitment of downstream 
signal transducers such as myeloid differentiation primary response protein 88 (MyD88), IL-1 
receptor-associated kinases (IRAKs), transforming growth factor (TGF) -% associated kinase-




All TLRs elicit conserved inflammatory pathways, culminating in the activation of nuclear 
factor (NF) -&B and activating protein-1 (AP-1), triggering slightly different patterns of gene 
expression profiles through the MyD88-dependent pathway as well as a poorly-understood 
MyD88-independent pathway, producing pro-inflammatory cytokines, which mediate direct 
defense responses and alert adaptive immune cells to the presence of a pathogen. For instance, 
activation of TLR3 and TLR4 result in induction of type I IFNs, but not when TLR2 or TLR5 
are activated (Doyle et al., 2002; Hoshino et al., 2002; Toshchakov et al., 2002). TLR7, 
TLR8 and TLR9 also lead to induction of type I IFNs, albeit by different mechanisms from 
the TLR3- and TLR4-mediated signaling pathways (Hemmi et al., 2003; Ito et al., 2002).  
 
TLRs, with the exception of TLR3, utilize the MyD88-dependent pathway, while TLR3 (and 
TLR4) use the MyD88-independent signaling pathway [Figure 1.4], which uses TIR-domain-
containing adaptor protein inducing IFN-$ (TRIF) as the adaptor molecule in place of MyD88 
(Takeda et al., 2003). Both pathways also activate the mitogen activated protein kinase 
(MAPK) cascade and the two main proteins of the cascade, c-Jun NH2-terminal kinase (Jnk) 
and p38 in turn activate the transcription factor, AP-1, which like NF-&B, triggers production 
of pro-inflammatory cytokines. 
 
 





1.4.4.1 MyD88-Dependent Pathway 
With its TIR domain, MyD88 is able to associate with the cytoplasmic TIR domain of TLRs 
directly for TLR7 and TLR9, or indirectly via the TIR-domain-containing adaptor protein 
(TIRAP) for TLR2 and TLR4. IRAKs are recruited to the receptor upon ligand binding and 
become activated upon phosphorylation. Activated IRAKs dissociate from the receptor 
complex and associate with TRAF6 instead, activating it. Subsequently the inhibitor of NF-
#B (I#B) is phosphorylated by the I&B-kinase (IKK) complex and nuclear translocation of 
NF-&B results, inducing the expression of pro-inflammatory cytokines, such as TNF-% and 
IL-6.  
 
1.4.4.2 MyD88-Independent Pathway 
In TLR3- and TLR4-mediated signaling pathways, activation of IFN-regulatory factor (IRF) 3 
and induction of IFN-$ are observed in a MyD88-independent manner. TRIF is essential for 
the MyD88-independent pathway and associates directly with the TIR domain of TLR3 or via 
the TRIF-related adaptor molecule (TRAM) for TLR4. TRIF associates with TBK1 and 
induces the phosphorylation and nuclear translocation of IRF3. The production of type I IFNs 
is further regulated by a positive feedback loop. IFN-$, which is produced in response to 
activated IRF3, can induce the transcription of genes encoding other signaling proteins such 
as IRF7 and IRF8 (Levy et al., 2002; Tailor et al., 2006). Once phosphorylated, these 
transcription factors drive the expression of all type I IFN genes, thereby amplifying type I 
IFN production. 
 
1.4.5 TLR Disease Associations  
TLR SNPs have been found to be associated with various diseases such as asthma, Crohn’s 
disease, systemic lupus erythematosus and type I diabetes mellitus and cancers such as 
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1.5 Published Data Thus Far 
1.5.1 KIR Associations with NPC 
To date, there has only been one published report on the associations between KIR and NPC 
(Butsch Kovacic et al., 2005) – a case-control study carried out in Taiwan on 295 cases and 
252 controls. Using high-resolution genotyping, the variation of HLA class I alleles and KIR 
alleles were evaluated. Two distinct hypotheses were proposed to describe a possible role of 
KIRs in the etiology of NPC and other viral-associated cancers. First, activating KIRs (and/or 
reduction in inhibitory KIRs) may be protective against NPC as a consequence of increased 
cytolysis of EBV-infected cells by activated NK cells. Alternatively, activating KIRs (and/or 
reduction in inhibitory KIRs) may increase risk of NPC through nonspecific inflammatory 
responses, such as oxidative DNA damage, triggered by activated NK cells. 
 
A correlation between increasing number of activating KIRs (KIR2DS and KIR3DS) and 
increasing NPC risk was established, particularly in individuals seropositive for anti-EBV 
antibodies that are known to be linked to NPC susceptibility (Ptrend = 0.07), with OR 
increasing from 2.0 in individuals with one activating KIR to 3.4 in individuals with at least 
five activating KIRs. Though none of the individual activating KIRs were found to be 
significantly associated with NPC, modest increases in risk associated with KIR2DS2 (OR = 
1.5), KIR2DS3 (OR = 1.4) and KIR3DS1 (OR = 1.4) were observed in EBV-seropositive 
individuals only. This lent credence to the hypothesis that activation of innate immune 
effector cells could increase risk of NPC. In contrast to activating KIRs, no overall suggestion 
exists that the risk of the disease was amplified by increasing number of inhibitory KIRs 
(KIR2DL and KIR3DL).  
 
A modest reduction in NPC risk was associated with HLA-C2 and Bw4 carriers, with OR of 
0.76 and 0.89 respectively. Comparing HLA-Cw alleles between cases and controls, a 
significant reduction for Cw*0401 was observed. A modest correlation (standard deviation, ' 




decrease risk of NPC). However, individuals with Cw*0401 but not A*1101 had a nearly 
three-fold reduction in NPC risk compared to individuals missing both alleles (OR = 0.37), 
suggesting that the effect of Cw*0401 was independent of the effect of A*1101. 
 
The results of the study were largely statistically insignificant but they marked the first 
insights into possible associations between NPC and KIR. 
 
1.5.2 TLR Associations with NPC 
There have been three published studies on the associations between TLR SNPs and NPC thus 
far (He et al., 2007; Song et al., 2006; Zhou et al., 2006), all of which were performed on 
unrelated Cantonese speakers who live in Guangdong, China, an area where NPC is endemic. 
The findings were summarized in Table 1.4 below. Zhou et al. also mentioned their findings 
of TLR1 SNP 130 T/C and TLR6 359 T/C being associated with NPC but no further details 
were provided, though it was stated that the paper(s) had been submitted for publication. 
 
Table 1.4 Published Data on TLR Associations with NPC. 
 
 
Intriguingly, the identified NPC-associated SNPs were located in non-coding regions. He et al. 
hypothesized that the intronic SNP identified did not contribute directly to the disease, but 
was only linked to an unknown causative SNP. Song et al. carried out in vitro studies by 
cloning the 3’-UTR of TLR4 into a firefly luciferase reporter plasmid, with both the variant 
(allele C) and wild type (allele G) alleles of SNP 11350. Results showed that the variant allele 




was associated with decreased mRNA stability and could downregulate TLR4 expression, 
resulting in increased risk of NPC. 
 
It would also appear that TLR haplotypes also play a prominent role in contributing to NPC 




1.6 Scope of Present Study 
As shown in the preceding sections, NPC is a human epithelial tumor of high incidence in the 
Southern Chinese population and EBV, HLA and environmental factors could play a part in 
its etiology. Given the contribution of EBV to the etiology of NPC, it would be interesting to 
consider the role played by the immune system in the pathogenesis of NPC. There are two 
branches of immunity, innate and adaptive immunity. Zheng et al.  proposed a 
complementary activation of NK cell-mediated immunity in NPC patients, where there was 
increased NK cell cytotoxicity against NPC cells in patients; while the reverse was observed 
in survivors in disease-free remission. Immune responses are activated sequentially from 
innate immunity to adaptive immunity – NK and #( T cells, which are broadly cytolytic, 
initially play dominant roles before target specific $% T cells take over. Thus, the reverse 
could be true when adaptive immunity is breached by tumors (Zheng et al., 2006). HLA, with 
its known genetic associations with NPC, belongs to the branch of adaptive immunity. Since 
HLA class I molecules are putative ligands for NK cells, a component of the innate immunity, 
we decided to investigate possible associations between NK cell receptors, specifically KIRs 
and TLRs, and NPC. The former recognizes specific HLA class I ligands whilst the latter 
recognizes PAMPs derived from pathogens, possibly EBV. 
 
Inhibitory KIRs interact with specific HLA class I ligands to impede NK cytolysis and protect 
‘self’ cells from spontaneous destruction, whereas activating KIRs stimulate NK cell-directed 
destruction of target cells, including transformed tumor cells and virus-infected cells. HLA-
Cw molecules are the predominant ligands for inhibitory KIRs (specifically KIR2DL1, 
KIR2DL2 and KIR2DL3). Given the striking homology between the extracellular domains of 
the activating KIR2DS1 and KIR2DS2, and their inhibitory counterparts, these receptors are 
likely to bind HLA-Cw molecules as well, albeit with lower affinity. Depending on the 
dimorphisms at residues 77 and 80, HLA-Cw molecules are classified into C1 or C2 groups 
that determine their specificities for a particular KIR. HLA-C1 allotypes are ligands for the 




molecules could also serve as ligands for KIRs, particularly Bw4 allotypes that are putative 
ligands of KIR3DL1 and KIR3DS1. The KIR binding specificity for HLA molecules raises 
the possibility that HLA-NPC associations reported previously reflect the involvement of 
both the adaptive and innate immune responses in NPC pathogenesis. Since many HLA 
molecules, in particular HLA-Bw4 and Cw molecules, are putative KIR ligands, the HLA 
association could be a clue to the underlying KIR disease associations.  
 
Given the great variation across populations, it would be necessary to characterize the KIR 
profile of the Singaporean population prior to carrying out disease association studies. 
Singapore is a multi-ethnic society, with a population primarily comprised of migrants and 
the various ethnic groups still retain individual genetic characteristics of their countries of 
origin. The distribution of KIR genes in the Singaporean population was studied by examining 
KIR gene contents of the three major ethnic groups – Chinese (174 samples), Malay (97 
samples) and Indians (102 samples), in Singapore. As of end June 2007, the Chinese, Malay 
and Indian ethnic groups constituted 75.0%, 13.7% and 8.7% of the Singaporean population 
(2008). Since NPC predominantly occurs in Chinese individuals, the KIR association study 
was restricted to Singaporean Chinese individuals only, with 96 NPC cases and 174 controls. 
 
Relatively little is known about the interaction of EBV with the TLR pathways or the 
mechanisms of EBV evasion of innate immune responses, though another pattern recognition 
receptor, retinoic acid-inducible gene I (RIG-I), has been reported to recognize EBV-encoded 
small RNAs (EBERs) and subsequently trigger production of type I IFN (Samanta et al., 
2006; Samanta et al., 2008). Human B cells express cell surface TLR1, TLR2 and TLR6, and 
endosomal TLR7, TLR9, and TLR10 (Hornung et al., 2002). Recent studies have shown that 
TLR signaling could be the third signal required for optimal B cell activation, in addition to 
antigen-binding to the B cell receptor and CD40 stimulation (Ruprecht and Lanzavecchia, 




proliferation (Martin et al., 2007); and EBV was shown to induce monocyte chemotactic 
protein 1 (MCP-1) secretion by human monocytes via TLR2 (Gaudreault et al., 2007). 
 
In contrast to direct ligation of EBV ligands to TLRs, EBV gene products could indirectly 
affect TLR signaling, as evidenced by a study done by Wang et al., where EBV latent 
membrane protein 2A (LMP2A) is proposed to induce a change in TLR signaling. LMP2A 
expression causes constitutive activation of the Ras/PI3K/Akt pathway and of NF-#B. Since 
TLRs, including TLR4, TLR7 and TLR9, also trigger the PI3K/Akt pathway leading to 
increased NF-#B activation, activation of this pathway by LMP2A may reduce the TLR 
signaling threshold (Wang et al., 2006).  
 
Armed with the evidence that NK cells could be directly involved in pathogen sensing 
through the TLRs they express, and that EBV infection is associated with NPC risk, we chose 
to examine the SNPs of specific TLR genes. Though highly conserved across a wide range of 
species, the genes involved in innate immunity display substantial inter-individual variability, 
predominantly in the form of SNPs. Genetic variation in such genes could play a role in 
determining susceptibility to a range of common chronic human diseases, which have an 
inflammatory component. We carried out a pilot study based on SNPs in TLR2, TLR4, TLR7, 
TLR8 and TLR9 of Singaporean Chinese, with 96 NPC cases and 96 controls. The method of 
SNP identification utilized was the selective re-sequencing of the regions of interest to 
identify putative novel SNPs as well as genotype known SNPs. For this pilot study, only the 
exons containing the coding sequences of each TLR (exons 2 of TLR2 and TLR9; exons 3 of 
TLR7 and TLR8) were sequenced. In the case of TLR4, only exon 3 was sequenced, which 
meant that approximately 300 bases from the start codon in exons 1 and 2 were omitted. 
Sequencing of these regions was carried out in an attempt to uncover nonsynonymous SNPs 
in the coding sequences that would result in amino acid changes, possibly altering the 
function or activity of a protein, thus affecting the immune system’s responses to EBV 




All selected TLRs have known viral ligands: the envelope proteins of measles virus, human 
cytomegalovirus (CMV) and herpes simplex virus type I for TLR2 (Bieback et al., 2002; 
Compton et al., 2003; Kurt-Jones et al., 2004); F protein of respiratory synctial virus (RSV) 
for TLR4 (Kurt-Jones et al., 2000); viral single-stranded RNA for TLR7 and TLR8; viral 
DNA for TLR9. Hence, they could play a role in the detection of EBV viral DNA. Though 
the viral ligands of TLR2 and TLR4 are for specific viruses, SNPs of TLR2 and TLR4 are 
well-characterized with many reported disease associations, making them a good starting 
point for a disease association study. Moreover, given that NPC is more frequent in males 
than females (2.3:1), we hypothesized that there might exist NPC-associated TLR7 and TLR8 
SNPs, since TLR7 and TLR8 are located on chromosome X. 
 
The scope of this study thus includes the following aspects: 
1. Characterize the KIR gene content of the Singaporean population – Chinese, Malay 
and Indian ethnic groups; 
2. Investigate the associations of NPC with KIR; 
3. Characterize the SNPs of TLR2, TLR4, TLR7, TLR8 and TLR9 in Singaporean 
Chinese and identify putative novel SNPs; 
4. Investigate the associations of NPC with TLR2, TLR4, TLR7, TLR8 and TLR9 SNPs. 
 
 CHAPTER 2 
MATERIALS AND METHODS 
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Media, Buffers and Solutions and Chemicals 
The media, buffers, solutions and chemicals used in this study are listed in Appendix I. 
 
2.1 Subjects 
All subjects were unrelated Singaporeans from whom appropriate informed consent were 
obtained and the samples taken were subsequently anonymized and de-linked from any 
identifiers. EBV-transformed B-lymphoblastoid cell lines (BLCLs) were established and 
stored frozen in liquid nitrogen at WHO Collaborating Centre for Research & Training in 
Immunology, Singapore.  
 
2.1.1 Controls  
Controls were composed of 373 healthy blood donors – 174 Chinese, 97 Malay and 102 
Indian. The Chinese samples, which were from donors originating primarily from Southern 
China, were also used as control subjects in the HLA and KIR disease association analyses. 
For TLR SNPs genotyping, a representative set of 96 Chinese samples was used. 
 
2.1.2 Cases 
Cases were composed of 96 Chinese originating primarily from Southern China. Cases were 
identified with pathologically confirmed diagnosis of NPC and had high EBV VCA-IgA and 
EA-IgA titers of & 1:640, an index of EBV activation. For TLR SNPs genotyping, all 96 NPC 
samples were used. 
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2.2 Cell Culture Techniques 
2.2.1 Growth of B-lymphoblastoid Cell Lines 
Frozen BLCLs, which were stored in liquid nitrogen, were thawed in a 37ºC water bath and 
resuspended in 10 ml RPMI [Appendix I] under sterile conditions. Cells were pelleted by 
centrifuging at 500 !g for five minutes and gently resuspended in 5 ml R10 [Appendix I] and 
transferred to a 25 ml culture flask, which was incubated in a 37ºC 5% CO2 incubator. The 
density of the cells was monitored and culture medium was added when necessary. When the 
total volume exceeded 15 ml, 80% of the cell culture was transferred to a 75 ml culture flask 
and 20 ml fresh R10 was added. 5 ml fresh R10 was added to the remaining cell suspension in 
the 25 ml flask. The resulting cell cultures were then incubated in a 37ºC 5% CO2 incubator 
until ready for freezing or harvesting. 
 
2.2.2 Freezing BLCLs 
Upon achieving 80% confluent growth, the cell culture in the 25 ml flask was centrifuged at 
500 !g for five minutes and the supernatant discarded. The pellet was resuspended in 1.5 ml 
ice-cold freezing mixture [Appendix I] and transferred to a labeled cryovial. This was kept at 
-70ºC for a minimum of two hours and a maximum of twenty-four hours before being 
transferred to liquid nitrogen storage at -196ºC. 
 
2.2.3 Harvesting BLCLs 
Upon achieving confluent growth, the cell culture in the 75 ml flask was centrifuged at 850 
!g for five minutes and the supernatant discarded. The cell pellet was then washed with 1 ml 
phosphate-buffered saline (PBS) [Appendix I] and centrifuged at 500 !g for five minutes 
with the supernatant once again discarded. The cell pellet was kept in a 2.0 ml centrifuge tube 
at -20ºC for short-term storage before DNA extraction. 
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2.3 Preparation of DNA Template for Genotyping  
2.3.1 Genomic DNA Extraction 
Genomic DNA was either extracted by the Autopure LS system using PureGene Chemistry 
(Gentra Systems, Minneapolis, MN, USA) or by using the QIAamp Blood Kit (QIAGEN 
GmbH, Germany) as per the manufacturer’s instructions.  
 
2.3.2 DNA Quality 
The quality of genomic DNA extracted was checked by gel electrophoresis, as good quality 
DNA was necessary for PCR amplification. DNA was deemed to be of good quality if the 
resulting band viewed under UV illumination was a single discrete band of high molecular 
weight and the ratio of absorbance at 260 nm to absorbance at 280 nm (A260/A280) is between 
1.8 and 2.0.  
 
2.3.3 DNA Quantification 
The concentration of DNA was determined using the NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA) and subsequently aliquoted and diluted 
with ddH2O to a final concentration of 100 ng/"l.  
 
2.3.4 DNA Storage 
DNA was stored at -20ºC for short-term storage and -80ºC for long-term storage. 
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2.4 HLA Genotyping  
2.4.1 PCR Amplifications of DNA Template 
PCR amplifications were carried out in a PTC-200 96-well Thermal Cycler (Bio-Rad 
Laboratories, Hercules, CA, USA). Primers were ordered from Sigma-Proligo (Singapore). 
Expand High Fidelity Taq polymerase (Roche Diagnostics GmbH, Germany) was used, along 
with the supplied 10) PCR buffer. dNTPs were purchased from Promega (Promega 
Corporation, Madison, WI, USA) and DMSO from Sigma (Sigma-Aldrich Inc, St. Louis, MO, 
USA). 
 
2.4.1.1 HLA-A, -B and -C PCR Amplifications of DNA Template 
PCR amplifications of HLA-A, -B and -C were performed in 30 "l reaction volumes 
containing 3 "l 10) PCR buffer (Roche), 3 "l 2 mM dNTPs (Promega) [Appendix I], 15 pmol 
primers [Table 2.1] (Sigma-Proligo), 1.5 "l DMSO (Sigma), 0.2 "l Taq polymerase (3.5 
U/"l) (Roche), 100 ng genomic DNA and ddH2O. PCR cycling conditions were as follows: 1 
cycle of 94ºC (2 min); 30 cycles of 94ºC (15 s), 65ºC (30 s), 72ºC (1 min); 1 cycle of 72ºC (7 
min); hold at 4ºC. 
 
Table 2.1 Oligonucleotide Primers for HLA-A, -B and -C PCR Amplifications. 
 
 
2.4.1.2 HLA-DRB1 PCR Amplifications of DNA Template 
PCR amplifications of HLA-DRB1 were performed in 30 "l reaction volumes containing 3 "l 
10) PCR buffer (Roche), 3 "l 2 mM dNTPs (Promega) [Appendix I], 15 pmol primers [Table 
2.2] (Sigma-Proligo), 0.2 "l Taq polymerase (3.5 U/"l) (Roche), 100 ng genomic DNA and 
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ddH2O. PCR cycling conditions were as follows: 1 cycle of 94ºC (2 min); 30 cycles of 94ºC 
(15 s), 63ºC (30 s), 72ºC (45 s); 1 cycle of 72ºC (7 min); hold at 4ºC. The expected product 
size of HLA-DRB1 PCR amplification was approximately 300 bp. 
 
Table 2.2 Oligonucleotide Primers for HLA-DRB1 PCR Amplifications. 
 
 
2.4.2 Sequencing of PCR Products 
2.4.2.1 Purification of PCR Products 
The PCR products were electrophoresed on 1% and 2% agarose gels for HLA-A, -B and -C 
and HLA-DRB1 respectively. The gel containing the correct sized amplicons are excised and 
the amplicons purified using the QIAquick Gel Extraction Kit (QIAGEN), as per the 
manufacturer’s instructions. 
 
 2.4.2.2 Cycle Sequencing Reactions 
The PCR products were sequenced using the ABI BigDye ® Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA, USA). 
 
In HLA-A, -B and -C sequence-based typing, exons 2 and 3 were sequenced to determine the 
genotype of the sample, thus two different primers were required; whilst only exon 2 was 
sequenced for HLA-DRB1 and hence only one primer – M13F, which recognizes the common 
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M13F tag added to the PCR amplicons by the common 3’ amplification primer, DRB1-91, 
was required. Some of the PCR primers could also be used for sequencing while additional 
sequencing primers were needed for others. The sequences of all the sequencing primers are 
shown in Table 2.3. 
 
Each sequencing reaction was carried out in a 10 "l reaction volume, containing 2 "l 
BigDye® Terminator Mix (Applied Biosystems), 1 "l 5) Sequencing Dilution Buffer 
(Applied Biosystems), 3 – 20 ng PCR product, 5 pmol primer (Sigma-Proligo) and ddH2O. 
Thermal cycling was performed in a PTC-200 96-well Thermal Cycler (Bio-Rad), with the 
following PCR cycling conditions: 1 cycle of 96ºC (1 min); 25 cycles of 96ºC (10 s), 50ºC (5 
s), 60ºC (4 min); hold at 4ºC. 
 
Table 2.3 Oligonucleotide Primers for HLA-A, -B, -C and -DRB1 Sequencing. 
 
 
2.4.2.3 Purification of Extension Products 
The extension products were purified using the ethanol/ sodium acetate precipitation method 
to remove excess dye terminators. To each sequencing reaction, 1 "l 3 M sodium acetate (pH 
5.1) and 25 "l absolute ethanol were added and the mixture thoroughly vortexed. The tubes 
were placed at -20ºC for fifteen minutes to allow precipitation of the extension products and 
then centrifuged at 16000 !g for fifteen minutes and the supernatant aspirated and discarded. 
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The pellet was rinsed with 200 "l 75% ethanol and centrifuged at 16000 !g for five minutes 
and the supernatant aspirated and discarded once again. The pellet was then dried at 70ºC for 
five minutes and stored at -20ºC till it is to be sequenced. 
 
2.4.2.4 Electrophoresis of Samples 
The dried DNA pellet was resuspended in 15 "l Hi-Di* Formamide (Applied Biosystems) 
and the samples were subsequently analyzed on an ABI 3100-Avant Genetic Analyzer 
(Applied Biosystems). The results were analyzed by the Sequencing Analysis Software v. 
5.1.1 (Applied Biosystems) and the electropherograms interpreted to determine the HLA-A, -B, 
-C and -DRB1 genotypes of the sample. 
Materials and Methods  
 
45
2.5 KIR Genotyping 
KIR genotyping was performed with sixteen PCR amplifications using sequence-specific 
primers (SSP-PCR) per individual (Gomez-Lozano and Vilches, 2002) to determine the 
presence or absence of sixteen KIR genes – KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, 
KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, 
KIR2DS5, KIR2DP1 and KIR3DP1, as each reaction is specific for a single KIR gene or 
pseudogene. 
 
2.5.1 KIR SSP-PCR Amplifications 
96-well PCR plates (Bio-Rad) were used and sealed with Microseal ‘F’ aluminized foils (Bio-
Rad), before being placed in a PTC-200 96-well Thermal Cycler (Bio-Rad) for PCR 
amplification.  
 
For each sample, sixteen individual reactions using different sets of primers were prepared. 
Most reactions contained one forward primer and one reverse primer; the exceptions being 
the reactions for KIR2DL1, KIR2DL3 and KIR3DP1 having three, four and three primers 
respectively. All reactions contained an internal positive control consisting of an additional 
pair of primers specific for the GH1 gene. 
 
Each PCR reaction was performed in a 20 "l reaction volume containing 2 "l 10) PCR buffer 
(Roche), 2 "l 2 mM dNTPs (Promega) [Appendix I], 10 pmol primer mix [Table 2.4] (Sigma-
Proligo), 1 "l DMSO (Sigma), 0.2 "l Taq polymerase (3.5 U/"l) (Roche), 50 ng genomic 
DNA and ddH2O. The PCR cycling conditions were as follows: 1 cycle of 94ºC (2 min); 10 
cycles of 94ºC (15 s), 60ºC (30 s), 72ºC (2 min); 20 cycles of 94ºC (15 s), 58ºC (30 s), 72ºC 
(2 min); hold at 4ºC. 
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2.5.2 Agarose Gel Electrophoresis of Amplicons 
The amplification products were electrophoresed on 1% agarose gels alongside an 
O’RangeRuler* 200 bp DNA ladder (Fermentas Life Sciences, Ontario, Canada) and 
revealed with ethidium bromide (Bio-Rad) under UV illumination and the gel interpreted to 
determine the KIR genotype of a sample. 
 
2.5.3 Interpretation of Agarose Gel Results 
The presence of an amplicon of the correct size implied the presence of the KIR gene, which 
the reaction was specific for and the intensity of the positive control in this case might be 
much weaker or even absent. However, the absence of any amplicon or the presence of an 
amplicon of the incorrect size implied the KIR gene that the reaction was specific for was 
absent, assuming the positive control was present. If the positive control was also absent, the 
SSP-PCR would be deemed to have failed and the experiment repeated.  
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2.6 TLR SNP Genotyping 
TLR SNP genotyping was carried out by selective re-sequencing of the entire coding 
sequences in exons 2 of TLR2 and TLR9, and exons 3 of TLR7 and TLR8. As for TLR4, 
only exon 3 was sequenced, which left out approximately 300 bases from the start codon in 
exons 1 and 2. The regions of interest were amplified by PCR and the resulting amplicons 
sequenced to determine the genotype of known SNPs as well as to identify putative novel 
SNPs, if any. The amplified sequences of each TLR gene and the complete list of SNPs 
genotyped in this study are given in Appendix II. 
 
2.6.1 PCR Amplifications of DNA Template 
PCR amplifications were carried out in 96-well PCR plates (Bio-Rad) and sealed with 
Microseal ‘F’ aluminized foils (Bio-Rad), before placing the plates in a PTC-200 96-well 
Thermal Cycler (Bio-Rad) for PCR amplification.  
 
2.6.1.1 PCR Amplifications of Exon 2 of TLR2 
PCR amplifications of TLR2 were performed in 50 "l reaction volumes containing 5 "l 10) 
PCR buffer (without Mg
2+
) (Roche), 5 "l 25 mM MgCl2 (Roche), 5 "l 2 mM dNTPs 
(Promega), 12.5 pmol primers TLR2F and TLR2R [Table 2.5] (Sigma-Proligo), 0.75 "l Taq 
polymerase (3.5 U/"l) (Roche), 100 ng genomic DNA and ddH2O. PCR cycling conditions 
were as follows: 1 cycle of 94ºC (2 min); 10 cycles of 94ºC (30 s), 60ºC (1 min), 68ºC (2 
min); 20 cycles of 94ºC (30 s), 58ºC (1 min), 68ºC (2 min); 1 cycle of 68ºC (7 min); hold at 
4ºC. 
 
2.6.1.2 PCR Amplifications of Exon 3 of TLR4 
PCR amplifications of TLR4 were performed in 50 "l reaction volumes containing 5 "l 10) 
PCR buffer (without Mg
2+
) (Roche), 2 "l 25 mM MgCl2 (Roche), 5 "l 2 mM dNTPs 
(Promega), 12.5 pmol primers TLR4F and TLR4R [Table 2.5] (Sigma-Proligo), 2 "l DMSO 
(Sigma), 0.75 "l Taq polymerase (3.5 U/"l) (Roche), 100 ng genomic DNA and ddH2O. PCR 
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cycling conditions were as follows: 1 cycle of 94ºC (2 min); 10 cycles of 94ºC (30 s), 68ºC (3 
min); 20 cycles of 94ºC (30 s), 66ºC (1 min), 68ºC (2 min); 1 cycle of 68ºC (7 min); hold at 
4ºC. 
 
2.6.1.3 PCR Amplifications of Exon 3 of TLR7 
PCR amplifications of TLR7 were performed in 50 "l reaction volumes containing 5 "l 10) 
PCR buffer (without Mg
2+
) (Roche), 2 "l 25 mM MgCl2 (Roche), 5 "l 2 mM dNTPs 
(Promega), 25 pmol primers TLR7F and TLR7R [Table 2.5] (Sigma-Proligo), 2.5 "l DMSO 
(Sigma), 0.75 "l Taq polymerase (3.5 U/"l) (Roche), 100 ng genomic DNA and ddH2O. PCR 
cycling conditions were as follows: 1 cycle of 94ºC (2 min); 10 cycles of 94ºC (15 s), 60ºC 
(30 s), 68ºC (2.5 min); 20 cycles of 94ºC (30 s), 58ºC (30 s), 68ºC (2.5 min); 1 cycle of 68ºC 
(7 min); hold at 4ºC. 
 
2.6.1.4 PCR Amplifications of Exon 3 of TLR8 
PCR amplifications of TLR8 were performed in 50 "l reaction volumes containing 5 "l 10) 
PCR buffer (without Mg
2+
) (Roche), 5 "l 25 mM MgCl2 (Roche), 5 "l 2 mM dNTPs 
(Promega), 25 pmol primers TLR8F and TLR8R [Table 2.5] (Sigma-Proligo), 2.5 "l DMSO 
(Sigma), 0.75 "l Taq polymerase (3.5 U/"l) (Roche), 100 ng genomic DNA and ddH2O. PCR 
cycling conditions were as follows: 1 cycle of 94ºC (2 min); 10 cycles of 94ºC (15 s), 58ºC 
(30 s), 68ºC (3 min); 20 cycles of 94ºC (30 s), 56ºC (30 s), 68ºC (3 min); 1 cycle of 68ºC (7 
min); hold at 4ºC. 
  
2.6.1.5 PCR Amplifications of Exon 2 of TLR9 
PCR amplifications of TLR9 were performed in 50 "l reaction volumes containing 5 "l 10) 
PCR buffer (without Mg
2+
) (Roche), 2 "l 25 mM MgCl2 (Roche), 5 "l 2 mM dNTPs 
(Promega), 25 pmol primers TLR9F and TLR9R [Table 2.5] (Sigma-Proligo), 0.75 "l Taq 
polymerase (3.5 U/"l) (Roche), 100 ng genomic DNA and ddH2O. PCR cycling conditions 
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were as follows: 1 cycle of 94ºC (2 min); 10 cycles of 94ºC (15 s), 68ºC (3 min); 20 cycles of 
94ºC (15 s), 66ºC (30 s), 68ºC (2.5 min); 1 cycle of 68ºC (7 min); hold at 4ºC. 
 
Table 2.5 Oligonucleotide Primers for TLR PCR Amplifications and Sequencing. 
 
 
2.6.2 Sequencing of PCR Products 
2.6.2.1 Purification of PCR Products 
The PCR products were purified using illustra GFX™ 96 PCR Purification Kit (GE 
Healthcare, Buckinghamshire, UK), as per the manufacturer’s instructions.  
 
2.6.2.2 Cycle Sequencing Reactions 
The PCR products were sequenced using the ABI BigDye ® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems). Sequencing reactions were carried out in MicroAmp* 
Optical 96-Well Reaction Plates (Applied Biosystems) and sealed with MicroAmp* Optical 
8-Cap Strips (Applied Biosystems). Each sequencing reaction is carried out in a 10 "l 
reaction volume, containing 4 "l BigDye® Terminator Mix (Applied Biosystems), 20 – 50 ng 
PCR product, 3.2 pmol primer (Sigma-Proligo) and ddH2O.  
 
PCR primers listed in Table 2.5 were also used as sequencing primers and additional 
sequencing primers are listed in Table 2.6. For each sample, a total of 30 sequencing reactions 
were performed to genotype TLR2, TLR4, TLR7, TLR8 and TLR9 SNPs – 5 reactions for 
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TLR2, 4 for TLR4, 6 for TLR7, 8 for TLR8 and 7 for TLR9. Sequencing primers were designed 
to sequence the genes with a minimum overlap of 50 bp between primers.  
 
Thermal cycling was performed in a PTC-200 96-well Thermal Cycler (Bio-Rad), with the 
following PCR cycling conditions: 1 cycle of 96ºC (1 min); 25 cycles of 96ºC (10 s), 50ºC (5 
s), 60ºC (4 min); hold at 4ºC. 
 
Table 2.6 Additional Oligonucleotide Primers for TLR Sequencing. 
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2.6.2.3 Purification of Extension Products 
The extension products were purified using the ethanol/ sodium acetate/ EDTA precipitation 
method to remove excess dye terminators. To each sequencing reaction, 1 "l 3 M sodium 
acetate (pH 5.1), 1 "l 125 mM sodium EDTA and 25 "l absolute ethanol were added and the 
plate was sealed before the plate was thoroughly vortexed. The plate was then placed in the 
dark at room temperature for fifteen minutes to allow precipitation of the extension products. 
The plate was then centrifuged at 3000 !g at 4ºC for thirty minutes. The supernatant was 
removed and discarded. The pellets were rinsed with 70 "l 75% ethanol and centrifuged at 
1650 !g at 4ºC for fifteen minutes and the supernatant removed and discarded once again. 
The pellets were left to dry at room temperature before being stored at -20ºC till they were to 
be sequenced. 
 
2.6.2.4 Electrophoresis of Samples 
The dried DNA pellets were resuspended in 15 "l of Hi-Di* Formamide (Applied 
Biosystems) and the samples were subsequently electrophoresed on an ABI 3100 Genetic 
Analyzer (Applied Biosystems).  
 
2.6.2.5 Analysis of TLR SNPs 
The results were analyzed by the Sequencing Analysis Software v. 5.1.1 (Applied 
Biosystems). The program, PolyPhred (Nickerson et al., 1997), was used to identify putative 
SNPs. All the genotyped results were checked to make sure they did not deviate from the 
Hardy-Weinberg equilibrium by performing Fisher’s exact test at a significance level of $ = 
10
-3
. To rule out genotyping errors and recently accrued mutations, only markers with a minor 
allele frequency (MAF) of at least 5% were used. The SNPs that passed these two criteria 
were deemed informative SNPs. 
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2.7 Statistical Analyses 
2.7.1 Haplotype Reconstruction 
The fastPHASE algorithm (version 1.2) based on a cluster model for haplotypes described in 
Scheet et al. (Scheet and Stephens, 2006) was used to reconstruct the HLA and TLR 
haplotypes from unphased genotype data of unrelated individuals. Parameters of the model 
are first estimated using an expectation-maximization algorithm; then conditional on these 
parameters, missing genotypes and haplotypes are inferred. Multiple iterations of the 
algorithm were executed and the average of the predictions were used.  
 
2.7.2 Fisher’s Exact Test 
The significance of differential frequencies of HLA-A, -B, -C, -DRB1, KIR or TLR alleles, 
phenotypes and genotypes between cases and controls were assessed in a 2)2 table using a 
two-tailed Fisher’s exact test. The p value is calculated as follows: 
! 
p =
a + b( )! a + c( )! b + d( )! c+ d( )!
a + b + c+ d( )!a!b!c!d!
 
 
2.7.3 2!3  !
2
 Test  
The significance of differential frequencies of TLR SNP genotypes (allele 1 homozygous, 
allele 2 homozygous and alleles 1 and 2 heterozygous) between cases and controls was 
assessed in a 2!3 table, using  !
2
 test with two degrees of freedom.  
 
2.7.4 Relative Risk and 95% Confidence Interval  
The strength of the association was assessed by calculating the relative risk (RR) with 95% 
confidence intervals (CI). RR of differential frequencies of HLA-A, -B, -C, -DRB1, KIR or 
TLR alleles, phenotypes and genotypes between cases and controls was assessed in a 2!2 
table, using the formulae (Woolf, 1955):  























2.7.5 Stratification Analyses  
In disease association studies, population subdivisions or recent admixture of populations 
could lead to spurious associations between a phenotype and unlinked candidate loci 
(Pritchard and Rosenberg, 1999). Where appropriate, stratifications according to gender and 
HLA haplotypes were implemented to determine if newly identified associations are spurious. 
Due to lack of data, stratification according to age of NPC onset could not be performed. 





3.1 KIR Population Studies 
3.1.1 KIR Gene Content of the Singaporean Population 
KIR PCR-SSP was carried out on a total of 174 Singaporean Chinese, 97 Malay and 102 
Indian samples to determine the presence or absence of the following KIR genes: KIR2DL1, 
KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, 
KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3 and KIR3DS1, and two pseudogenes, KIR2DP1 
and KIR3DP1. The distribution of KIR genes in the Singaporean population, illustrated in 
Table 3.1 and Figure 3.1, was based on the KIR gene content of the three major local ethnic 
groups – Chinese, Malay and Indian.  
 
The framework genes (KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1) were present in all 
individuals except one Indian who lacked KIR2DL4, and all other genes were found in each 
ethnic group. The genes, KIR2DL1 and KIR2DP1, could be found in almost all of the 
individuals, with frequencies greater than 95% for all three ethnic groups. KIR2DL3 and 
KIR2DS4 had similar distributions, with frequencies ranging between 84% and 99% for all 
three ethnic groups. The remaining genes varied amongst the ethnic groups, with KIR2DL2, 
KIR2DS2 and KIR3DL1 exhibiting the greatest variations, ranging from 18 – 20 % in Chinese, 
to 39 – 41% in Malay, to 66% in Indian for KIR2DL2 and KIR2DS2; and KIR3DL1 which 
was present in 89% Chinese, 61% Malay and 49% Indian.  
 
The Chinese and Indian ethnic groups displayed the greatest dissimilarities between each 
other, while the Malay and Indian ethnic groups were the most similar to each other. In 
addition to the three genes mentioned above (KIR2DL2, KIR2DS2 and KIR3DL1), the 
frequencies of KIR2DL3, KIR2DL5, KIR2DS1, KIR2DS3, KIR2DS4 and KIR2DS5 also 
differed significantly with p < 0.01 between the Chinese and Indian ethnic groups. The 
Chinese and Malay ethnic groups were more similar, with frequencies of KIR2DL3 and 
KIR2DL5 varying with p < 0.01. The Malay and Indian ethnic groups had no significant 




Table 3.1 KIR Profile of Singaporean Population. KIR PCR-SSP was carried out on a total 
of 174 Singaporean Chinese, 97 Malay and 102 Indian samples to determine the presence or 
absence of various KIR genes. The total number of KIR genes within each ethnic group is 









































































































































































3.1.2 KIR Genotypes and Haplotypes  
Based on their gene content, two groups of KIR haplotypes, A and B, have been described. 
Currently, the types of activating and inhibitory KIR genes present distinguish these 
haplotype groups. According to this new KIR haplotype group definition, group B haplotypes 
possess different combinations of KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and 
KIR3DS1 genes, whereas group A haplotypes possess a single activating gene, KIR2DS4, as 
well as four inhibitory genes encoding proteins representing the main HLA class I 
specificities, KIR2DL1, KIR2DL3, KIR3DL1 and KIR3DL2 (Marsh et al., 2003). In this study, 
KIR genotypes are determined based on the above KIR haplotype definitions and grouped into 
genotypes AA, AB and BB depending on the KIR genes present.  
 
A total of 81 unique KIR genotypes were identified amongst the Singaporean Chinese, Malay 
and Indian ethnic groups, of which only six genotypes had frequencies of 5% or higher in at 
least one of the ethnic groups. Table 3.2 lists all the KIR genotypes and their frequencies in 
each ethnic group and a summary is provided in Table 3.3, showing the compiled frequencies 




























































































































































































































































































































































Table 3.3 KIR Genotypes AA, AB and BB, and Haplotypes A and B in Singaporean 




Genotypes AA and AB were much more common, compared to genotype BB, in Singaporean 
Chinese and Malay. Genotype AA was present in 57% and 33% of Chinese and Malay 
respectively, and genotype AB, 37% and 57% respectively. On the other hand, genotype BB 
was present in only 5% of Chinese and 10% of Malay. Singaporean Indian had similar 
proportions of genotypes AA and BB (~ 16 – 17% each) and 68% of genotype AB. The most 
common genotype for all three ethnic groups was genotype AA4 of KIR2DL1, KIR2DL3, 
KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS4, KIR2DP1 and KIR3DP1, with 51% in 
Chinese, 26% in Malay and 10% in Indian. 
 
KIR haplotypes A and B were evenly distributed in Singaporean Indian (50% each) in 
contrast to Chinese and Malay, where haplotype A was more common, occurring in 76% of 




3.2 NPC Case Control Association Analyses 
3.2.1 HLA Associations with NPC 
For the disease association analyses, HLA class I (HLA-A, -B and -C) and class II (HLA-
DRB1) allotypes for 174 controls and 96 NPC cases were successfully determined at the 
allelic level using sequence-based typing methods.  
 
3.2.1.1 Phenotypic and Allelic HLA Associations 
Distributions of HLA phenotypes and alleles in NPC cases and controls were examined and a 
total of 19 HLA-A, 41 HLA-B, 21 HLA-C and 29 HLA-DRB1 alleles were identified in both 
NPC cases and controls. Selected results are shown in Table 3.4. 
 
Certain HLA phenotypes such as HLA-A*0207, A*3303, B*1301, B*4601 and B*5801, 
which were reported to be associated with NPC, did not show significant differences between 
cases and controls in this study. Aside from this, the results showed a number of novel 
phenotypes with significant associations with NPC. Cw*0702 (26% vs. 39%; p = 0.033, RR = 
0.55) and B*5502 (2% vs. 10%; p = 0.023; RR = 0.20) were observed to be decreased in 
cases compared to controls; whereas A*2402 (33% vs. 21%; p = 0.028; RR = 1.92), Cw*1402 
(16% vs. 6%; p = 0.017; RR = 2.74) and B*5101 (17% vs. 7%; p = 0.024, RR = 2.48) were 
increased in cases compared to controls. HLA-DRB1 phenotypes exhibited no marked 
differences between cases and controls.  
 
Distribution of HLA alleles appeared to mirror the distribution of HLA phenotypes, with 
similar HLA alleles displaying significant associations with NPC (p < 0.05). But A*1101 was 
an exception, where a significant association of the allele was observed (20% vs. 33%; p = 
0.001; RR = 0.51), though not for the A*1101 phenotype. In addition, homozygosity for 
A*1101 was observed in approximately 13% of our study population, thus the effect of 
A*1101 homozygosity on NPC risk could be examined. 31 out of 174 (18%) controls 




Table 3.4 Distribution of Selected HLA Phenotypes and Alleles in Cases and Controls. 
HLA genotyping was carried out on 96 cases and 174 controls, and selected HLA phenotypes 
and alleles identified are shown below, together with their frequencies. Statistically 







3.2.1.2 Phased HLA Haplotypes  
Using the fastPHASE algorithm, HLA haplotypes were inferred from the genotypes and the 
distribution of HLA haplotypes was then examined using the phased haplotypes. Selected 
results are shown in Table 3.5. 
 
The distribution of certain HLA haplotypes (A*0207-Cw*0102-B*4601 and A*3303-
Cw*0302-B*5801-DRB1*0301), which are known to be in linkage disequilibrium, showed 
no significant difference in cases compared to controls. The occurrence of the haplotype 
A*1101-Cw*0702-B*4001 was less frequent in cases than controls (1% vs. 5%; p = 0.003; 
RR = 0.10); whereas the haplotype Cw*1402-B*5101 was found to occur more frequently in 
cases than controls (7% vs. 3%; p = 0.023; RR = 2.74). 
 
Table 3.5 Distribution of Selected Phased HLA Haplotypes in Cases and Controls. HLA 
haplotypes were inferred from the genotypes using the fastPHASE algorithm. Selected phased 
HLA haplotypes and their frequencies are shown below. Statistically significant results with p 





3.2.2 KIR Associations with NPC  
KIR genotyping was successfully carried out for 96 cases and associations with NPC were 
examined by comparing KIR genotypes of these 96 cases with 174 controls. 
 
3.2.2.1 Inhibitory KIRs  
There was no overall indication that the risk of disease was associated with the number of 
inhibitory KIRs (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2 and 
KIR3DL3) [Figure 3.2]. As most of the inhibitory KIRs (except KIR2DL2 and KIR2DL5) 
were nearly ubiquitous in the study population, a baseline of four to five inhibitory KIRs was 
established. Relative risks ranged from 1.17 in individuals with four to five inhibitory KIRs to 
0.80 in individuals with six inhibitory KIRs to 1.69 in individuals with seven inhibitory KIRs.  
 
 
Figure 3.2 Associations of NPC with Number of Inhibitory KIRs. KIR genotyping was 
carried out for 96 cases and 174 controls. The number of inhibitory KIRs present in each 
sample was counted and the results collated. 62 cases and 106 controls had 4 – 5 inhibitory 
KIRs; 20 cases and 43 controls had 6 inhibitory KIRs; 14 cases and 16 controls had 7 
inhibitory KIRs. No statistically significant results were found. 
 
Examining the effects of individual inhibitory KIRs [Table 3.6], only KIR3DL1 was found to 
be significantly decreased in cases compared to controls (75% vs. 89%; p = 0.006; RR = 0.39. 




KIR2DL2 and KIR2DL5, had relative risks less than 1. The exceptions KIR2DL2 and 
KIR2DL5 could be explained by the complete linkage disequilibrium that exists with the two 
KIR genes and the activating KIR genes, KIR2DS2, KIR2DS3 and KIR2DS5. 
 
Table 3.6 Effects of Individual Inhibitory KIRs in Cases and Controls. KIR genotyping 
was carried out for 96 cases and 174 controls. The counts and frequencies of the various 
inhibitory KIRs were determined. Statistically significant results with p < 0.05 are highlighted 
in yellow. KIR3DL1 was found to be protective against NPC.  
 
 
Stratification according to HLA was carried out to further explore the protective effect of 
KIR3DL1, where individuals with either a protective allele (A*1101, Cw*0702, B*5502 or 
B*2704) or a protective haplotype A*1101-Cw*0702-B*4001, as determined in section 3.2.1, 
were removed from the sample pool and the associations re-examined [Table 3.7]. All the 
significant associations remained, except the non A*1101 individuals, suggesting that the 
protective effect of KIR3DL1 was independent of protective HLA alleles or haplotype. The 
loss of significance observed in non A*1101 individuals could be explained by the large 
number of A*1101 individuals present in the study, which might reduce the power of the 
statistical test. But when the protective haplotype A*1101-Cw*0702-B*4001 was considered, 
the significance remained (76% vs. 89%, p = 0.007, RR = 0.38), implying that the KIR3DL1 




Table 3.7 Stratification Results for KIR3DL1 in Cases and Controls. The protective effect 
of KIR3DL1 was examined in greater detail. Samples containing KIR3DL1 were stratified to 
rule out possible confounders that were found to be protective against NPC in the previous 
section such as HLA-A*1101, Cw*0702, B*5502 and B*2704 alleles, or A*1101-Cw*0702-
B*4001 haplotype. Statistically significant results with p < 0.05 are highlighted in yellow. 
The results imply that KIR3DL1 does indeed confer a protective effect.  
 
 
3.2.2.2 Activating KIRs  
When the activating KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1 
and KIR2DL4) were examined, a trend for risk to increase with increasing number of 
activating KIRs was observed [Figure 3.3]. The risks increased from 0.71 for individuals with 
two or three activating KIRs to 1.02 for individuals with between four and five activating 
KIRs to 2.87 for individuals with at least six activating KIRs. The number of individuals with 
at least six activating KIRs was significantly decreased in controls compared to cases (14% vs. 






Figure 3.3 Associations of NPC with Number of Activating KIRs. KIR genotyping was 
carried out for 96 cases and 174 controls. The number of activating KIRs present in each 
sample was counted and the results collated. 54 cases and 112 controls had 2 – 3 activating 
KIRs; 29 cases and 52 controls had 4 – 5 activating KIRs; 13 cases and 9 controls had ' 6 
activating KIRs. * indicates a p-value < 0.05.  
 
Although none of the individual activating KIRs were found to be significantly associated 
with NPC, the risks associated with the activating KIRs were modestly increased, ranging 
from 1.20 for KIR2DS3 to 1.69 for KIR2DS4 as shown in Table 3.8. 
 
Table 3.8 Effects of Individual Activating KIRs in Cases and Controls. KIR genotyping 
was carried out for 96 cases and 174 controls. The counts and frequencies of the various 






3.2.2.3 KIR Genotypes and Haplotypes  
KIR genotypes observed in cases were similar to KIR genotypes observed in Singaporean 
Chinese controls [Table 3.9] and genotype AA4 was also the most common genotype, being 
observed in 40.6% of cases. The distribution of haplotypes A and B were similar in both cases 
and controls, where haplotype A was more prevalent, with frequencies of at least 72%, 
compared to haplotype B. 
 
Table 3.9 KIR Genotypes AA, AB and BB, and Haplotypes A and B in Cases and 
Controls.  KIR genotyping was carried out on 96 cases and 174 controls using PCR-SSP. KIR 
genotypes were classified into AA, AB or BB depending on the KIR genes present and KIR 
haplotypes can be subsequently inferred from the KIR genotypes. 
 
 
3.2.2.4 KIRs with their HLA Ligands 
Under the premise that KIR functions require the presence of their respective ligands, we 
examined the effects of KIRs in the presence or absence of their putative HLA ligands (HLA-
Bw4, -C1 and -C2). Dimorphisms in the HLA-Cw $1 domain, characterized by Ser77/Asn80 
and Asn77/Lys80, define serologically distinct allotypes of HLA-Cw, C1 and C2, 
respectively, while HLA-B allotypes with the serologically-defined motif, Bw4, are 





, as previous reports suggest that Bw4 with an isoleucine at residue 80 was a 
better ligand for KIR3DL1 and possibly KIR3DS1 compared to threonine at the same 
position, as Bw4
Ile80
 was able to confer protection against the development of hepatocellular 




AIDS (Lopez-Vazquez et al., 2005a; Martin et al., 2002). The list of examined KIRs and their 
putative ligands were summarized in Table 3.10.  
 
Table 3.10 Examined KIRs and Their Ligands. Assuming that KIRs require their ligands 




To rule out any possible confounding effects effected by HLA ligands, the ligands themselves 
were examined for possible associations with NPC [Table 3.11]. Analyses of HLA-A*03, 
A*11 and Cw*04 had already been carried out in section 3.2.1.1, where only A*1101 was 
found to be significantly lowered in cases than controls. Neither of the Bw4, C1 nor C2 
ligands achieved statistical significance.  
 
Table 3.11 Associations Between KIR Ligands and NPC. To eliminate possible 
confounding effects of HLA ligands, HLA ligands were first examined independently of the 
KIR genes in their associations with NPC. No statistically significant associations were found.  
 
 
Table 3.12 shows the KIRs in the presence of their respective ligands in cases and controls. 
Where the KIRs were present together with their ligands, the risks were generally elevated, 





Table 3.12 KIRs in the Presence of Their Ligands in Cases and Controls. Assuming KIRs 
require their ligands to become functional, KIRs in the presence of their ligands were 
examined in their associations with NPC. No statistically significant associations were found. 
 
 
The number of KIRs was re-examined in the presence of their HLA ligands as shown in 
Figure 3.4. There remains no correlation between relative risk and the number of inhibitory 
KIRs in the presence of their ligands; though the number of activating KIRs in the presence of 
their ligands mirrored the trend of increasing relative risk with increasing number of 
activating KIRs previously displayed in Figure 3.3. The relative risk increased from 0.79 for 
individuals without any activating KIRs with their ligands to 1.00 for individuals with one 
activating KIR with ligands to 2.15 for individuals with at least two activating KIRs with 
ligands. Comparing between individuals with at least two activating KIRs with ligands, cases 









Figure 3.4 Associations of NPC with Number of KIRs in the Presence of Their Ligands. 
(A) Inhibitory KIRs in the presence of their ligands: 13 cases and 33 controls had one 
inhibitory KIR that was present with its ligands; 76 cases and 133 controls had 2 – 3 
inhibitory KIRs that were present with their ligands; 7 cases and 13 controls had 4 – 5 
inhibitory KIRs that were present with their ligands.  (B) Activating KIRs in the presence of 
their ligands: 51 cases and 108 controls had no activating KIRs that were present with their 
ligands; 27 cases and 49 controls had one activating KIR that was present with its ligand; 31 
cases and 18 controls had ' 2 activating KIRs that were present with their ligands. ** 
indicates a p-value < 0.01. 
 
To further explore the effects the putative ligands have on the KIRs, various combinations 
were analyzed – (i) when both the KIR and its ligand were absent [this was set as the 




(iii) when the ligand was present, regardless of the presence of the KIR; (iv) when both the 
KIR and its ligand were present; (v) when the KIR was present but its ligand was absent; (vi) 
when the ligand was present but the KIR was absent. No significant associations were 
uncovered, except in the case of KIR3DL1. 
 
Both KIR3DL1 and KIR3DS1 segregate as alleles of the same locus and are known to bind the 
same ligand, HLA-Bw4. Table 3.13 shows the frequencies of KIR3DL1, KIR3DS1 and their 
ligand, HLA-Bw4 and specifically HLA-Bw4
Ile80
, in cases and controls.  
 
In both comparisons, a KIR3DL1 homozygous genotype in the absence of its ligand was 
associated with a decreased risk for NPC (17% vs. 28%; p = 0.038; RR = 0.51 for Bw4 
ligand; 28% vs. 47%; p = 0.003; RR = 0.44 for Bw4
Ile80
 ligand). In addition, the reverse was 
true for KIR3DS1 homozygous genotype in the absence of specific Bw4
Ile80
 ligands, which 
was associated with an increased risk of 3.26 (10% vs. 3%; p = 0.029). 
 
Table 3.13 KIR3DL1, KIR3DS1 and HLA-Bw4 Ligand in Cases and Controls. . 
KIR3DL1 and KIR3DS1 segregate as alleles of the same locus and are known to bind to the 
same ligand, HLA-Bw4; thus samples containing KIR3DL1, KIR3DS1 or both are examined 
in the presence or absence of the Bw4 ligand, and the Bw4
Ile80 
subgroup. Statistically 





To eliminate possible contributing effects from KIR3DS1, KIR3DL1 [Figure 3.4; Table 3.14] 
was examined in the absence of KIR3DS1. Also included in Figure 3.4 were references of 
data from all individuals and individuals with KIR3DS1. For individuals with neither 
KIR3DL1 nor Bw4 ligand, RR was set to 1.00.  
 
As seen from Figure 3.5, the trend observed for all three sets of data (total, KIR3DS1+ and 
KIR3DS1- individuals) mirrored one another. KIR3DL1, on the whole, was associated with a 
lower risk, which was consistent with the results of the preceding section, especially when 
KIR3DL1 was present without its ligand. A significant decrease in RR was shown when 
KIR3DL1 was present without its Bw4
Ile80
 ligand in individuals without KIR3DS1 (p = 0.012; 
RR = 0.13), individuals with KIR3DS1 (p = 0.040; RR = 0.23) and all individuals (p = 0.001; 
RR = 0.11). 
 
 
Figure 3.5 Joint Effects of KIR3DL1 and Its Ligand in Individuals Without KIR3DS1. 
Data from all individuals and individuals with KIR3DS1 were shown as references. Relative 
risks were compared using individuals with neither KIR3DL1 nor its ligand as the baseline (RR 
= 1.00). The trends observed for all data sets mirrored one another, and KIR3DL1 is associated 



























































































































































































































































































































































































































































Of the various inhibitory KIRs, only KIR2DL1 (HLA-C2), KIR2DL2 (HLA-C1), KIR2DL3 
(HLA-C1) and KIR3DL1 (HLA-Bw4) have known ligands. Thus the absence of KIR 
(indicated by ‘0’) and presence of KIR in the absence (indicated by ‘-’) or presence (indicated 
by ‘+’) of its ligand were examined [Table 3.15]. The most common combination of KIRs 
and ligands was used as a reference of RR = 1.00. 
 
The most common combination was the absence of KIR2DL2, the presence of KIR2DL1 
without its ligand and the presence of KIR2DL3 and KIR3DL1 in the presence of their 
respective ligands (29% vs. 29%; p = ns; RR = 1.00). Only one particular combination 
achieved statistical significance – absence of KIR2DL2, presence of KIR2DL1 and KIR3DL1 
in the absence of their respective ligands and presence of KIR2DL3 in the presence of its 





Table 3.15 KIR2DL1, KIR2DL2, KIR2DL3 and KIR3DL1 and their Ligands in Cases 
and Controls.  Inhibitory KIRs with known ligands are further examined. ‘+’ indicates the 
presence of a ligand and ‘-’ indicates the absence of a ligand in the presence of the KIR; ‘0’ 







Of the various activating KIRs, only KIR2DS1 (HLA-C2), KIR2DS2 (HLA-C1) and 
KIR3DS1 (HLA-Bw4) have known HLA ligands. Thus the absence of KIR (indicated by ‘0’) 
and presence of KIR in the absence (indicated by ‘-’) or presence (indicated by ‘+’) of its 
ligand were examined [Table 3.16]. The most common combination of KIR and ligands was 
used as a reference of RR = 1.00. 
 
The most common combination was an absence of all three activating KIRs (48% vs. 59%; p 
= ns; RR = 1.00). As before, only one combination reached statistical significance – presence 
of KIR2DS1 and KIR3DS1 in the absence of their ligands and presence of KIR2DS2 in the 
presence of its ligand (9% vs. 2%; p = 0.004; RR = 9.08). 
 
Table 3.16 KIR2DS1, KIR2DS2 and KIR3DS1 and their Ligands in Cases and Controls. 
Activating KIRs with known ligands are further examined. ‘+’ indicates the presence of a 
ligand and ‘-’ indicates the absence of a ligand in the presence of the KIR; ‘0’ indicates the 





The overall KIR and ligand combinations, which integrated both the inhibitory and activating 
KIRs in the preceding sections, were then examined and selected results were shown in Table 
3.17. The most common combination of KIR and ligands was used as a reference of RR = 
1.00. 
 
The most common combination was a combination of the two most frequent combinations of 
activating and inhibitory KIRs, i.e. absence of KIR2DL2, KIR2DS1, KIR2DS2 and 
KIR3DS1; presence of KIR2DL1 in the absence of its ligand; presence of KIR2DL3 and 
KIR3DL1 in the presence of their ligands (24% vs. 21%; p = ns; RR = 1.00). Only one 
combination achieved statistical significance – absence of KIR2DL2, KIR2DS1, KIR2DS2 
and KIR3DS1; presence of KIR2DL1 and KIR3DL1 in the absence of their ligands; presence 










































































































































































































































The joint effects of KIR and their HLA ligands in the KIR genotype AA4 were explored. As 
determined in section 3.2.3.3, AA4 was the most common KIR genotype in cases and controls, 
containing the following KIR genes – KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, 
KIR3DL3, KIR2DS4, KIR2DP1 and KIR3DP1. Of these KIRs, only KIR2DL1 (HLA-C2), 
KIR2DL3 (HLA-C1) and KIR3DL1 (HLA-Bw4) have known ligands. Thus these three KIRs 
were considered in the presence and absence of their respective ligands as shown in Table 
3.18.  
 
The most common combination is absence of ligand for KIR2DL1 and presence of ligands for 
KIR2DL3 and KIR3DL1. Only one combination achieved statistical significance – presence 
of KIR2DL1 and KIR3DL1 in the absence of their ligands and presence of KIR2DL3 in the 
presence of its ligand (18% vs. 39%; p = 0.026; RR = 0.15).  
 
Table 3.18 KIR2DL1, KIR2DL3 and KIR3DL1 and their Ligands in Individuals with 
KIR Genotype AA4. Genotype AA4 was the most common genotype determined in the 
previous section. The various KIRs with known ligands in the genotype are further examined. 
‘+’ indicates the presence of a ligand and ‘-’  indicates the absence of a ligand. Statistically 
significant results with p < 0.05 are highlighted in yellow. 
 
 
3.2.2.5 Stratification Analyses 
Stratification analyses according to HLA haplotype and gender were also carried out, but no 




3.2.3 TLR Associations with NPC 
3.2.3.1 TLR SNP Genotyping Results 
SNP genotyping by selective re-sequencing for TLR2, TLR4, TLR7, TLR8 and TLR9 was 
carried out on 96 NPC cases and 96 Chinese controls as a pilot study, of which only 80 cases 
and 86 controls could be successfully genotyped for all SNPs. Briefly, TLR coding sequences, 
namely exons 2 of TLR2 and TLR9, and exons 3 of TLR7 and TLR8, and exon 3 of TLR4 
which omitted ~ 300 bp of coding sequences in the preceding exons were amplified by PCR 
and subsequently sequenced. SNPs were identified using the PolyPhred algorithm. The 
complete list of SNPs that were genotyped in this study is given in Appendix II. SNPs that 
satisfied Hardy-Weinberg equilibrium at a significance level of $ = 10
-3
 and had a minor 
allele frequency (MAF) of at least 5% were considered informative SNPs. 
 
TLR2 
A total of seventeen SNPs, spanning 2526 bp, were successfully genotyped on TLR2. Twelve 
SNPs were homozygous for all the samples and of the remaining SNPs, two had a MAF less 




A total of nineteen SNPs, spanning 2445 bp, were successfully genotyped on TLR4. 
Seventeen of the SNPs were homozygous for all the samples and the two remaining SNPs had 
MAF less than 5%, thus there were no informative SNPs for TLR4. 
 
TLR7 
A total of fifteen SNPs, spanning 3532 bp, were successfully genotyped on TLR7. Thirteen of 
the SNPs were homozygous for all the samples and the two remaining SNPs had MAF less 






A total of twenty-four SNPs, spanning 4396 bp, were successfully genotyped on TLR8. 
Nineteen of the SNPs were homozygous for all the samples and the five remaining SNPs had 
MAF greater than 5%, thus there were five informative SNPs for TLR8 – rs2159377, 
rs5744080, rs2407992, rs3747414 and rs5744088. 
 
TLR9 
A total of fourteen SNPs, spanning 3212 bp, were successfully genotyped on TLR9. Thirteen 
of the SNPs were homozygous for all the samples and the remaining SNP had a MAF greater 
than 5%, thus there was only one informative SNP for TLR9 – rs352140. 
 
Informative SNPs for the various TLRs were summarized in Table 3.19. It is worthwhile to 
note that all informative SNPs were synonymous, without any amino acid changes. 
 
Table 3.19 Summary of Informative TLR SNPs.  Of the five TLRs examined by selective 
re-sequencing of major exons in 80 cases and 86 controls, three, five and one informative 
SNPs were identified for TLR2, TLR8 and TLR9 respectively. All informative SNPs identified 






3.2.3.2 Individual TLR SNP Analyses 
Firstly, each TLR SNP was tested for the allelic and genotypic associations with NPC by 
means of Fisher’s exact test.  
 
Allelic Distributions of Individual TLR SNPs 
The allelic distributions for each informative SNP were summarized in Table 3.20. As TLR8 
is located on chromosome X, the total count of alleles would be 2n for females and n for 
males, where n = number of samples. No statistically significant associations were ascertained.  
 
Table 3.20 Allelic Distributions of Individual TLR SNPs. 80 cases and 86 controls were 
successfully genotyped for all the specified TLR SNPs. The allelic counts and frequencies for 




Genotypic Distributions of Individual TLR SNPs  
The genotypic distributions for each informative SNP (homozygotes and heterozygotes) were 

























































































































































































3.2.3.3 TLR Phenotypes 
The distributions of the phenotypes for TLR2 and TLR8 were summarized in Table 3.22. No 
statistically significant associations were established. 
 
Table 3.22 Distribution of TLR2 and TLR8 Phenotypes. The TLR2 and TLR8 phenotypes 
comprised of the three and five informative SNPs respectively are determined for each 








3.2.3.4 Phased TLR Haplotypes 
TLR2 and TLR8 phenotypes were analyzed by the computer algorithm, fastPHASE, to infer 
their phased haplotypes [Table 3.23]. No statistically significant associations were identified.  
 
Table 3.23 Distribution of Phased TLR2 and TLR8 Haplotypes. The TLR2 and TLR8 
haplotypes were inferred from the phenotypes using the fastPHASE algorithm and the 




3.2.3.5 Stratification Analyses 
Stratification analyses according to HLA haplotypes and gender were also carried out, but no 
significant associations were uncovered. As shown in Figure 3.6, the frequencies of the TLR2 
and TLR8 SNPs mirrored the frequencies of NPC cases and controls, displaying no 









Figure 3.6 Distributions of TLR2 and TLR8 SNPs in Different HLA Haplotypes. The 
frequencies of the informative TLR2 and TLR8 SNPs in individuals with different HLA 
haplotypes were plotted against their relative genetic distances from one another. Curves for 
the cases and controls are shown as references. (A) TLR2; (B) TLR8. As the various curves 
for the different HLA haplotypes mirrored the reference curves, it is evident that there are no 










4.1 KIR Gene Content of Singaporean Population 
Singapore is a migrant society, composed mainly of Chinese (75.0%), Malay (13.7%) and 
Indian (8.7%) (2008), who remain genetically distinct from one another, retaining the 
characteristics of their countries of origin. Thus the KIR gene contents of each of the three 
ethnic groups were determined separately to reflect the true nature of the Singaporean 
population. SSP-PCR was carried out to determine the presence or absence of sixteen KIR 
genes - KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, 
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR2DP1 and KIR3DP1, in each 
individual.  
 
Amongst the three ethnic groups, the Chinese and Indian ethnic groups displayed the greatest 
dissimilarities between each other and the Malay and Indian ethnic groups were the most 
similar to each other. Other than the framework loci (KIR2DL4, KIR3DL2, KIR3DL3 and 
KIR3DP1), genes such as KIR2DL1, KIR2DL3, KIR2DP1 and KIR2DS4 were present in most 
individuals, with a frequency of at least 84% in each ethnic group. KIR2DL2, KIR2DS2 and 
KIR3DL1 exhibited the greatest variation across the three ethnic groups.  
 
The results from this study were then compared to previously published reports of various 
Asian and American populations [Table 4.1]. Compared to the published KIR gene 
frequencies of Singaporean Chinese (Middleton et al., 2008), both sets of data were largely 
similar and most of the gene frequencies had a difference of 5% or less, but three observed 
frequencies had differences up to 10% (KIR2DL2 - 8%; KIR2DS2 - 10%; KIR3DL1 - 9%). 
Comparing the published data of various Chinese populations from China (Jiang et al., 2005; 
Williams et al., 2003), Hong Kong (Middleton, 2005), Singapore (Middleton et al., 2008) and 
Taiwan (Yen et al., 2006), the Taiwanese Chinese population appeared to be the most 
dissimilar with great differences (> 25%) in the frequencies of KIR2DL1, KIR2DL2 and 
KIR2DS2. Thus, excluding the data from the Taiwanese Chinese population, our data was 




comparable to the other Chinese populations from China and Hong Kong, with frequencies 
falling between the maximum and minimum reported frequencies of the various KIR genes. 
No published data exists for populations similar to the Singaporean Malay ethnic group such 
as Malaysia, or Indonesia, thus no comparisons could be made.  
 
Comparisons could be made between the Singaporean Indian ethnic group and the North 
Indian population (Rajalingam et al., 2002) since a fraction of the Singaporean Indians had 
migrated from North India to Singapore. With the exception of KIR3DL1 (49% vs. 87.5%), 
the frequencies of the other genes appeared similar.  
 
Published data suggests the KIR gene frequencies vary between populations. Certain genes, 
other than the four framework genes, exist in similar frequencies in different populations, 
while the frequencies of other genes differ widely across populations. The former includes 
KIR2DL1, KIR2DL3, KIR2DS4, KIR3DL1 and KIR2DP1, differing by less than 10% between 
most populations. The greatest variations were observed in the frequencies of KIR2DL2, 
KIR2DL5 and KIR2DS2 with differences of more than 35% across different populations. Thus 
it was necessary to determine the KIR profile of the Singaporean population before the KIR 
disease association analysis was carried out. 
 
A total of 81 unique KIR genotypes were identified amongst the Chinese, Malay and Indian 
ethnic groups – 5 AA genotypes, 19 BB genotypes and 57 AB genotypes, of which only six 
genotypes had frequencies of 5% or higher in at least one of the ethnic groups. Genotypes AA 
and AB were much more common in Chinese and Malay compared to genotype BB. 
Genotype AB was more common in Indian, with genotypes AA and BB present in similar 
proportions. For all three ethnic groups, the most common genotype was AA4, which 
contained KIR2DL1, KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS4, 
KIR2DP1 and KIR3DP1, present in 51% Chinese, 26% Malay and 10% Indian.  
 




Haplotype A was more common in Singaporean Chinese and Malay. The observation that 
Singaporean Chinese had 76% of haplotype A corresponded to previous reports that 
haplotype A was more frequent in Han Chinese, with a frequency of about 75% (Jiang et al., 
2005). The Indian ethnic group, however, had equal distributions of both haplotypes A and B, 
making it similar to Caucasian populations (Hsu et al., 2002b; Uhrberg et al., 1997). 



























































































































































































































































































































































































4.2. HLA Associations with NPC 
HLA associations with NPC were first identified in Singapore, where A*0207-Cw*0102-
B*4601 and A*3303-Cw*0302-B*5801-DRB1*0301 were found to be associated with 
increased relative risks (Chan, 1990; Chan et al., 1983); a consistent negative association with 
the alleles A11 and B13 (Chan, 1990) was also uncovered. Previous HLA association studies 
conducted in southern China have also reported positive associations of NPC with the alleles 
A2, B14 and B46, and negative associations with the alleles A11, B13 and B22 (Goldsmith et 
al., 2002). 
 
For this study, we failed to discover any statistically significant associations between NPC 
and B*1301, possibly due to the small sample size; though we verified the protective effect of 
the A*1101 allele. Novel associations were discovered – alleles Cw*0702 and B*5502 were 
found to be protective, while alleles Cw*1402 and B*5101 were found to increase NPC risk 
of individuals. No significant associations between NPC and the A2B46 and A33B58 
haplotypes were found, though novel significant haplotypic associations were uncovered – the 
haplotype A*1101-Cw*0702-B*4001 was found to be protective with RR = 0.10, while the 
Cw*1402-B*5101 haplotype was associated with an increased risk of 2.74. 




4.3 KIR Associations with NPC 
4.3.1 Hypotheses About KIR Disease Associations 
Given that many KIR ligands are HLA-B and HLA-Cw alleles, and studies have shown HLA 
associations with NPC, we hypothesized that there might exist similar associations between 
KIR and NPC. Activated NK cells, a result of increased activation by activating KIRs and/or 
decreased inhibition by inhibitory KIRs could either cause an increased cytolysis of EBV-
infected cells thus conferring a protective effect; or they could trigger non-specific 
inflammatory responses, creating an increased susceptibility to NPC. 
 
4.3.2 Number of KIRs 
Examining the number of activating KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, 
KIR2DS5, KIR3DS1 and KIR2DL4) alone, ignoring their ligands, we observed a trend of 
increasing risk with increasing number of activating KIRs, as RR increases from 0.71 in 
individuals with two or three activating KIRs to 2.87 in individuals with at least six activating 
KIRs. Further examination revealed the same trend of increasing risk with increasing number 
of activating KIRs in the presence of their putative HLA ligands as RR increased from 0.79 
for individuals without any activating KIRs with their ligands to 1.00 for individuals with one 
activating KIR with ligands to 2.15 for individuals with at least two activating KIRs with 
ligands. Such a trend could be supportive of the second hypothesis that increased activation of 
NK cells may trigger non-specific inflammatory responses, thus increasing the individual’s 
risk for NPC. No similar correlation was discovered for the inhibitory KIRs. 
 
4.3.3 Effects of Individual KIRs 
When the KIRs were examined singly, only KIR3DL1 was found to be significantly 
associated with a lowered risk (RR = 0.39), indicating a possible protective role played by 
KIR3DL1. To remove possible confounding effects contributed by HLA, stratification by 
protective HLA alleles and haplotypes were carried out and the significance of the association 




between KIR3DL1 and NPC remained, implying that the protective effect of KIR3DL1 was 
independent of the protective effects of the HLA molecules. 
 
Though there were no significant associations observed for the other KIRs, it was interesting 
to note that activating KIRs were associated with increased relative risks, while inhibitory 
KIRs were generally associated with decreased relative risks (except KIR2DL2 and KIR2DL5, 
which could be explained by the complete linkage disequilibrium that exists between these 
KIR genes and the activating KIR2DS2, KIR2DS3 and KIR2DS5 genes). Such observations 
once again corroborated with the evidence in the preceding section – activation of NK cells 
by activating KIRs result in non-specific inflammatory responses that increase risk of NPC; 
and the converse is true of inhibitory KIRs. 
 
4.3.4 Individual KIRs And Their Ligands 
With the presupposition that KIR functions are dependent on the presence of their ligands, we 
explored the effects of KIRs in the presence or absence of their putative HLA ligands. 
KIR3DL1 was the only receptor that exhibited novel associations with NPC. 
 
KIR3DL1, on the whole, was associated with decreased risk, which corroborated with the 
negative association observed with KIR3DL1 allele alone. This association reached statistical 
significance when KIR3DL1 was in the absence of its Bw4 ligand. This observation held true 
when various scenarios were examined, lending credence to the hypothesis that KIR3DL1 
without its ligand is unable to inhibit NK cells. As a result, there is increased cytolysis of 
EBV-infected cells by activated NK cells, leading to a decreased risk. 
 




, as previous 
reports have suggested that Bw4 with an isoleucine at residue 80 is a better ligand for 
KIR3DL1 and possibly KIR3DS1 compared to threonine at the same position, because 
Bw4
Ile80
 is able to confer protection against the development of hepatocellular carcinoma 




(Lopez-Vazquez et al., 2005b) and delays progression of HIV-1 infection into AIDS (Lopez-
Vazquez et al., 2005a; Martin et al., 2002). This was verified in this study as analyses using 
Bw4
Ile80
 reached statistical significance when analyses using Bw4 ligand failed to. But this 
would have to be verified with in vitro experiments. 
 
4.3.5 Combinations of Multiple KIRs And Their Ligands 
KIRs with known HLA ligands (KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1, KIR2DS1, 
KIR2DS2 and KIR3DS1) and their respective ligands were examined and some observations 
were made. The most common combinations observed were often possible subsets of the 
genotype AA4, the most common genotype, where the KIRs were present as per the AA4 
genotype, but ligands could either be present or absent. 
 
Examination of the combinations for inhibitory KIRs (KIR2DL1, KIR2DL2, KIR2DL3 and 
KIR3DL1) revealed that the only combination to attain statistical significance was a 
protective combination that included KIR3DL1 present without its ligand – the absence of 
KIR2DL2, presence of KIR2DL1 and KIR3DL1 in the absence of their ligands and presence 
of KIR2DL3 with its ligand. However, when KIR3DL1 was removed from the analysis, none 
of the combinations reached statistical significance, suggesting that KIR3DL1 without its 
ligand was the main factor that contributed to the statistical significance of the combination. 
This corroborated with the preceding section. 
 
When comparing the combinations for the activating KIRs (KIR2DS1, KIR2DS2 and 
KIR3DS1), the only combination to achieve statistical significance was a combination where 
all three KIRs were present and ligands for KIR2DS2 and KIR3DS1 were present but the 
ligand for KIR2DS1 was absent. Such a combination was associated with an increased risk, 
which corroborated the trend of increased risk observed for increasing number of activating 
KIRs. The combination where all three KIRs and their ligands were present was rare, being 
only observed in one case and one control. On the other hand, the most common combination 




was when all three KIRs were absent, as per genotype AA4, and that was associated with a 
lowered risk. Taken together, this suggested that the activation of NK cells by activating KIRs 
result in non-specific inflammatory responses that increase risk of NPC. 
 
Due to the possibility that various common combinations were actually part of the AA4 
genotype, individuals with the AA4 genotype were subjected to further analyses. Of all the 
KIRs present in the AA4 genotype, only KIR2DL1, KIR2DL3 and KIR3DL1 had known 
ligands. Thus, when the combinations for those KIRs were examined, only the combination 
where the ligands for KIR2DL1 and KIR3DL1 were absent and the ligand for KIR2DL3 was 
present, was found to be significantly protective, which once again supports the previous 
observations that KIR3DL1 in the absence of its ligand is protective. 
 
4.3.6 Limitations of Present Study 
From the results thus far, it appears that both hypotheses suggested remain likely and it is not 
possible, within the scope of this study, to narrow down which is the exact mechanism at 
work, if the hypotheses were indeed the correct one. 
 
For the purposes of this study, we only determined the presence or absence of KIR genes. 
This severely underestimates KIR diversity, in terms of the number of KIR genes present on 
each haplotype and in terms of the different KIR alleles present. Multiple copies of 
KIR3DL1/3DS1 and KIR2DL4 were identified in some individuals (Williams et al., 2003) and 
this gene duplication could result in additive effects of KIR genes. Such diversity makes it 
challenging to carry out KIR genotyping on samples.  
 
Our incomplete understanding of NK cell and KIR biology and the poorly understood ligands 
of KIRs hamper the analyses, as there could exist unknown ligands that might confound the 
analysis. Recently, a paper has demonstrated that ligand interactions are allele-specific 
(Thananchai et al., 2007). Given the close homology between the HLA molecules, the HLA-




C1, C2 and Bw4 sequence motifs could be found in the other HLA class I molecules, making 
it possible for KIRs to bind other ligands of another HLA group. Thananchai et. al. used 
peptide-HLA class I tetrameric complexes to illustrate that A*2402, a HLA-A molecule that 
contains the Bw4 motif, is able to bind to certain KIR3DL1 alleles, but not others. The same 
laboratory had previously demonstrated that KIR3DL2 specificity is dependent on the HLA 
class I molecule (either A*03 or A*11) as well as the bound peptide (derived from EBV) 
(Hansasuta et al., 2004). 
 
To date, there has only been one published report on the possible associations between KIR 
and NPC, in which most of the results were not statistically significant but they could provide 
a hint to the underlying associations. The same applies for this study. This study confirmed 
the published observation that activating KIRs are associated with increased risk; it also 
suggested a protective role played by KIR3DL1, particularly in the absence of its HLA-Bw4 
ligand. This would suggest that activated NK cells in both cases would result in either 
increased non-specific inflammatory responses and thus increase risk of NPC, or increased 
cytolysis of EBV-infected cells and thus decrease risk of NPC. Further independent studies 
would be required to confirm the link between KIRs and innate immunity to NPC 
pathogenesis. 




4.4 TLR Associations with NPC 
4.4.1 Hypothesis About TLR Disease Associations 
EBV infections are part of the etiology of NPC, thus TLRs, which are integral to innate 
immunity in pathogen sensing, could play a part in NPC pathogenesis. We hypothesized there 
exist TLR SNPs that could alter the function of the TLR, tempering the innate immune 
response to EBV, thus affecting an individual’s risk for NPC.  
 
As a pilot study, we selectively re-sequenced major exons of interest of TLR2, TLR4, TLR7, 
TLR8 and TLR9 to genotype known SNPs and identify putative novel SNPs, if any, in 96 
cases and 96 controls, of which 80 cases and 86 controls were successfully genotyped for all 
SNPs. All the genotyped results were checked to ensure they did not deviate from the Hardy-
Weinberg equilibrium by performing Fisher’s exact test at significance level of $ = 10
-3
. To 
rule out genotyping errors and recently accrued mutations, only markers with a minor allele 
frequency (MAF) of at least 5% were used. The SNPs that passed these two criteria were 
deemed as informative SNPs. No putative novel SNPs with a MAF of at least 5% were 
identified. 
 
4.4.2 Informative TLR SNPs 
No informative SNPs were identified for TLR4 and TLR7, out of the nineteen and fifteen 
SNPs genotyped respectively. TLR2 had three informative SNPs (rs3804099, rs3804100 and 
rs5743705) out of the seventeen genotyped; TLR8 had five informative SNPs (rs2159377, 
rs5744080, rs2407992, rs3747414 and rs5744088) out of the twenty-four genotyped and 
TLR9 had one informative SNP (rs352140) out of fourteen genotyped SNPs. It is worthwhile 
to note that all the informative SNPs were synonymous SNPs that do not have changes in the 
amino acid encoded. This suggests that the amino acids were essential in determining the 
conformations and subsequently, the functions of the TLRs. Any amino acid changes that 
result in decreased activity of the TLRs might have been selected against. 




4.4.3 Comparisons With Published Data 
The results of our study were compared to the International HapMap project, specifically the 
results of the Han Chinese population in Beijing, China, as that is the most genotypically 
similar to the Singaporean Chinese ethnic group. 
 





Compared to the International HapMap data for Han Chinese in Beijing, China, most of the 
allele frequencies of the various TLR SNPs were similar, with the exceptions of rs3804099 
and rs3804100 for TLR2 and rs352140 for TLR9. The differences could be due to differences 
between both populations. 
 
4.4.4 TLR Associations With NPC 
Various aspects of the TLR2, TLR8 and TLR9 SNPs data were analyzed – allelic and 
genotypic distributions, combined phenotypes and phased haplotypes but no significant 
associations were identified. The data were stratified according to HLA haplotypes and gender 
but no significant associations were discovered. Stratification by age of onset of NPC could 
not be performed due to lack of information. 
 




In all, we conclude that TLR2, TLR4, TLR7, TLR8 and TLR9 did not have any NPC-associated 
SNPs in their exons. Looking at published data, it is possible that such SNPs lie in non-coding 
regions instead such as 3’UTR or 5’UTR, which could affect the expression of TLR or in 
introns where they serve an unknown function, perhaps as a marker that is in tight linkage 
disequilibrium with a yet unidentified marker. 
 
4.4.5 Limitations of Present Study 
Despite the fact that large differences were not observed between subjects, the inability to 
genotype all participants diminished the statistical power of the study. The inability to 
successfully genotype all participants could be caused by technical difficulties of amplifying 
PCR fragments of lengths exceeding 3 kb. As a result, subjects who could not be genotyped 
for all the 89 examined SNPs of TLR2, TLR4, TLR7, TLR8 and TLR9 were eliminated. Since 
only major exons were examined, it is possible that disease-associated SNPs are actually 
located elsewhere in the genome, perhaps in the non-coding regions.  





The present study illustrates the variability of KIR gene distributions across populations and 
even within the Singaporean population, distinct differences exists between the ethnic groups. 
KIR has many putative HLA-B and HLA-Cw ligands and given the known HLA associations 
with NPC, associations between KIR and NPC could exist, if HLA was indeed a causal link in 
NPC. More studies into the associations between KIR and NPC would have to be carried out 
to validate our findings and those of Butsch Kovacic (Butsch Kovacic et al., 2005). Though 
no TLR2, TLR4, TLR7, TLR8 and TLR9 coding SNPs were found to be associated with NPC, 
it remains possible that intronic SNPs or SNPs in non-coding regions could be associated, 
thus further investigations are warranted. 
 
The findings of this thesis are inconclusive. Ignoring the absence of NPC association found 
between TLR2, TLR4, TLR7, TLR8 and TLR9 coding SNPs, the conclusions drawn from 
KIR analyses suggest that that the role of NK cells remains unclear. Evidence hints at either 
possibility of NK cells being protective or driving NPC pathogenesis.  
 
With increasing numbers of activating KIRs in the presence of their ligands, the relative risk 
of NPC increases, implying that activating KIRs, in the presence of their ligands, result in 
activation of NK cells, which could result in the production of pro-inflammatory cytokines 
that trigger non-specific responses, such as oxidative DNA damage. This corroborated the 
findings of a previous report by Butsch Kovacic et al. (2005). However, KIR3DL1, an 
inhibitory KIR, is found to confer a protective effect, especially in the absence of its HLA-
Bw4 ligand, which implies that KIR3DL1 is unable to inhibit NK-mediated killing in the 
absence of its ligand, and hence NK cells are able to proceed with cytolysis, possibly of EBV-
infected cells, thus decreasing the risk for NPC. This is a novel finding and will need to be 
confirmed by further independent studies. More studies would be required to confirm the link, 
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Appendix I Buffers and Solutions 
Where stated, the solutions were sterilized by autoclaving at 121ºC for fifteen minutes. 
 
I. Tissue Culture 
a. RPMI-1640 Medium 
 
 
One packet of RPMI powder (Gibco BRL, USA), HEPES, L-glutamine, sodium pyruvate 
and glucose were dissolved in 5 L of ddH2O. NaHCO3 (separately dissolved) was then 
added and the pH adjusted to 7.20. Another 5 L of ddH2O is added. The medium was 
sterilized by double-filtration through .22 "m filter, aliquoted in 500 ml and stored at 4ºC. 
 
b. Fetal Calf Serum (FCS) 
500 ml of fetal calf serum (Cytosystems, Australia) was thawed in a 37ºC water bath and 




Penicillin-streptomycin (Gibco BRL, USA) was thawed in a 37ºC water bath, aliquoted 
and stored at 4ºC. It is used at a dilution of 1:100. 
 




d. Freezing Mixture 
 
 
The mixture was filter sterilized and stored at 4ºC. 
 
e. R10 Medium 
 
 
The medium was stored at 4ºC. 
 
f. 10! Phosphate-Buffered Saline (PBS) 
 
 
The solution was autoclaved and stored at room temperature. 




II. Molecular Biology Work 
a. 2 mM dNTPs  
 
 
The solution was stored at -20ºC. 
 
b. 10! Tris-Borate Buffer (TBE) 
 
 
The buffer was autoclaved and stored at room temperature. 
 
c. Ficoll Loading Buffer 
 
 
The buffer was filtered and stored at 4ºC. 








LOCUS   NC_000004 (TLR2) 2525 bp    DNA linear   CON 03-MAR-2008 
DEFINITION  Homo sapiens chromosome 4, reference assembly, complete sequence. 
ACCESSION   NC_000004 REGION: 154843455..154845980 
ORIGIN    
   1 tcaaacacaa tgacttattt gaacctcttt tatttgtagg ttgaagcact ggacaatgcc  
  61 acatactttg tggatggtgt gggtcttggg ggtcatcatc agcctctcca aggaagaatc  
 121 ctccaatcag gcttctctgt cttgtgaccg caatggtatc tgcaagggca gctcaggatc  
 181 tttaaactcc attccctcag ggctcacaga agctgtaaaa agccttgacc tgtccaacaa  
 241 caggatcacc tacattagca acagtgacct acagaggtgt gtgaacctcc aggctctggt  
 301 gctgacatcc aatggaatta acacaataga ggaagattct ttttcttccc tgggcagtct  
 361 tgaacattta gacttatcct ataattactt atctaattta tcgtcttcct ggttcaagcc  
 421 cctttcttct ttaacattct taaacttact gggaaatcct tacaaaaccc taggggaaac  
 481 atctcttttt tctcatctca caaaattgca aatcctgaga gtgggaaata tggacacctt  
 541 cactaagatt caaagaaaag attttgctgg acttaccttc cttgaggaac ttgagattga  
 601 tgcttcagat ctacagagct atgagccaaa aagtttgaag tcaattcaga atgtaagtca  
 661 tctgatcctt catatgaagc agcatatttt actgctggag atttttgtag atgttacaag  
 721 ttccgtggaa tgtttggaac tgcgagatac tgatttggac actttccatt tttcagaact  
 781 atccactggt gaaacaaatt cattgattaa aaagtttaca tttagaaatg tgaaaatcac  
 841 cgatgaaagt ttgtttcagg ttatgaaact tttgaatcag atttctggat tgttagaatt  
 901 agagtttgat gactgtaccc ttaatggagt tggtaatttt agagcatctg ataatgacag  
 961 agttatagat ccaggtaaag tggaaacgtt aacaatccgg aggctgcata ttccaaggtt  
1021 ttacttattt tatgatctga gcactttata ttcacttaca gaaagagtta aaagaatcac  
1081 agtagaaaac agtaaagttt ttctggttcc ttgtttactt tcacaacatt taaaatcatt  
1141 agaatacttg gatctcagtg aaaatttgat ggttgaagaa tacttgaaaa attcagcctg  
1201 tgaggatgcc tggccctctc tacaaacttt aattttaagg caaaatcatt tggcatcatt  
1261 ggaaaaaacc ggagagactt tgctcactct gaaaaacttg actaacattg atatcagtaa  
1321 gaatagtttt cattctatgc ctgaaacttg tcagtggcca gaaaagatga aatatttgaa  
1381 cttatccagc acacgaatac acagtgtaac aggctgcatt cccaagacac tggaaatttt  
1441 agatgttagc aacaacaatc tcaatttatt ttctttgaat ttgccgcaac tcaaagaact  
1501 ttatatttcc agaaataagt tgatgactct accagatgcc tccctcttac ccatgttact  
1561 agtattgaaa atcagtagga atgcaataac tacgttttct aaggagcaac ttgactcatt  
1621 tcacacactg aagactttgg aagctggtgg caataacttc atttgctcct gtgaattcct  
1681 ctccttcact caggagcagc aagcactggc caaagtcttg attgattggc cagcaaatta  
1741 cctgtgtgac tctccatccc atgtgcgtgg ccagcaggtt caggatgtcc gcctctcggt  
1801 gtcggaatgt cacaggacag cactggtgtc tggcatgtgc tgtgctctgt tcctgctgat  
1861 cctgctcacg ggggtcctgt gccaccgttt ccatggcctg tggtatatga aaatgatgtg  
1921 ggcctggctc caggccaaaa ggaagcccag gaaagctccc agcaggaaca tctgctatga  
1981 tgcatttgtt tcttacagtg agcgggatgc ctactgggtg gagaacctta tggtccagga  
2041 gctggagaac ttcaatcccc ccttcaagtt gtgtcttcat aagcgggact tcattcctgg  
2101 caagtggatc attgacaata tcattgactc cattgaaaag agccacaaaa ctgtctttgt  
2161 gctttctgaa aactttgtga agagtgagtg gtgcaagtat gaactggact tctcccattt  
2221 ccgtcttttt gatgagaaca atgatgctgc cattctcatt cttctggagc ccattgagaa  
2281 aaaagccatt ccccagcgct tctgcaagct gcggaagata atgaacacca agacctacct  
2341 ggagtggccc atggacgagg ctcagcggga aggattttgg gtaaatctga gagctgcgat  
2401 aaagtcctag gttcccatat ttaagaccag tctttgtcta gttgggatct ttatgtcact  

















LOCUS   NC_000009 (TLR4) 2445 bp    DNA linear   CON 03-MAR-2008 
DEFINITION  Homo sapiens chromosome 9, reference assembly, complete sequence. 
ACCESSION   NC_000009 REGION: 119514362..119516806 
ORIGIN    
   1 ttgcctatgc acaatcatat gacccatcac atctgtatga agagctggat gactaggatt  
  61 aatattctat tttaggttct tattcagcag aaatattaga taatcaatgt ctttttattc  
 121 ctgtaggtgt gaaatccaga caattgaaga tggggcatat cagagcctaa gccacctctc  
 181 caccttaata ttgacaggaa accccatcca gagtttagcc ctgggagcct tttctggact  
 241 atcaagttta cagaagctgg tggctgtgga gacaaatcta gcatctctag agaacttccc  
 301 cattggacat ctcaaaactt tgaaagaact taatgtggct cacaatctta tccaatcttt  
 361 caaattacct gagtattttt ctaatctgac caatctagag cacttggacc tttccagcaa  
 421 caagattcaa agtatttatt gcacagactt gcgggttcta catcaaatgc ccctactcaa  
 481 tctctcttta gacctgtccc tgaaccctat gaactttatc caaccaggtg catttaaaga  
 541 aattaggctt cataagctga ctttaagaaa taattttgat agtttaaatg taatgaaaac  
 601 ttgtattcaa ggtctggctg gtttagaagt ccatcgtttg gttctgggag aatttagaaa  
 661 tgaaggaaac ttggaaaagt ttgacaaatc tgctctagag ggcctgtgca atttgaccat  
 721 tgaagaattc cgattagcat acttagacta ctacctcgat gatattattg acttatttaa  
 781 ttgtttgaca aatgtttctt cattttccct ggtgagtgtg actattgaaa gggtaaaaga  
 841 cttttcttat aatttcggat ggcaacattt agaattagtt aactgtaaat ttggacagtt  
 901 tcccacattg aaactcaaat ctctcaaaag gcttactttc acttccaaca aaggtgggaa  
 961 tgctttttca gaagttgatc taccaagcct tgagtttcta gatctcagta gaaatggctt  
1021 gagtttcaaa ggttgctgtt ctcaaagtga ttttgggaca accagcctaa agtatttaga  
1081 tctgagcttc aatggtgtta ttaccatgag ttcaaacttc ttgggcttag aacaactaga  
1141 acatctggat ttccagcatt ccaatttgaa acaaatgagt gagttttcag tattcctatc  
1201 actcagaaac ctcatttacc ttgacatttc tcatactcac accagagttg ctttcaatgg  
1261 catcttcaat ggcttgtcca gtctcgaagt cttgaaaatg gctggcaatt ctttccagga  
1321 aaacttcctt ccagatatct tcacagagct gagaaacttg accttcctgg acctctctca  
1381 gtgtcaactg gagcagttgt ctccaacagc atttaactca ctctccagtc ttcaggtact  
1441 aaatatgagc cacaacaact tcttttcatt ggatacgttt ccttataagt gtctgaactc  
1501 cctccaggtt cttgattaca gtctcaatca cataatgact tccaaaaaac aggaactaca  
1561 gcattttcca agtagtctag ctttcttaaa tcttactcag aatgactttg cttgtacttg  
1621 tgaacaccag agtttcctgc aatggatcaa ggaccagagg cagctcttgg tggaagttga  
1681 acgaatggaa tgtgcaacac cttcagataa gcagggcatg cctgtgctga gtttgaatat  
1741 cacctgtcag atgaataaga ccatcattgg tgtgtcggtc ctcagtgtgc ttgtagtatc  
1801 tgttgtagca gttctggtct ataagttcta ttttcacctg atgcttcttg ctggctgcat  
1861 aaagtatggt agaggtgaaa acatctatga tgcctttgtt atctactcaa gccaggatga  
1921 ggactgggta aggaatgagc tagtaaagaa tttagaagaa ggggtgcctc catttcagct  
1981 ctgccttcac tacagagact ttattcccgg tgtggccatt gctgccaaca tcatccatga  
2041 aggtttccat aaaagccgaa aggtgattgt tgtggtgtcc cagcacttca tccagagccg  
2101 ctggtgtatc tttgaatatg agattgctca gacctggcag tttctgagca gtcgtgctgg  
2161 tatcatcttc attgtcctgc agaaggtgga gaagaccctg ctcaggcagc aggtggagct  
2221 gtaccgcctt ctcagcagga acacttacct ggagtgggag gacagtgtcc tggggcggca  
2281 catcttctgg agacgactca gaaaagccct gctggatggt aaatcatgga atccagaagg  
2341 aacagtgggt acaggatgca attggcagga agcaacatct atctgaagag gaaaaataaa  
2401 aacctcctga ggcatttctt gcccagctgg gtccaacact tgttc 
// 
 




Table A.2: Examined TLR4 SNPs. 
 
 





LOCUS   NC_000023 (TLR7) 3482 bp    DNA linear   CON 03-MAR-2008 
DEFINITION  Homo sapiens chromosome X, reference assembly, complete sequence. 
ACCESSION   NC_000023 REGION: 12813467..12816948 
ORIGIN    
   1 caaaagagag gcagcaaatg ggaattttta attctgattc ttggtatgtt ttagaacaat  
  61 gatttgttct ttcttatact ttcaggtgtt tccaatgtgg acactgaaga gacaaattct  
 121 tatccttttt aacataatcc taatttccaa actccttggg gctagatggt ttcctaaaac  
 181 tctgccctgt gatgtcactc tggatgttcc aaagaaccat gtgatcgtgg actgcacaga  
 241 caagcatttg acagaaattc ctggaggtat tcccacgaac accacgaacc tcaccctcac  
 301 cattaaccac ataccagaca tctccccagc gtcctttcac agactggacc atctggtaga  
 361 gatcgatttc agatgcaact gtgtacctat tccactgggg tcaaaaaaca acatgtgcat  
 421 caagaggctg cagattaaac ccagaagctt tagtggactc acttatttaa aatcccttta  
 481 cctggatgga aaccagctac tagagatacc gcagggcctc ccgcctagct tacagcttct  
 541 cagccttgag gccaacaaca tcttttccat cagaaaagag aatctaacag aactggccaa  
 601 catagaaata ctctacctgg gccaaaactg ttattatcga aatccttgtt atgtttcata  
 661 ttcaatagag aaagatgcct tcctaaactt gacaaagtta aaagtgctct ccctgaaaga  
 721 taacaatgtc acagccgtcc ctactgtttt gccatctact ttaacagaac tatatctcta  
 781 caacaacatg attgcaaaaa tccaagaaga tgattttaat aacctcaacc aattacaaat  
 841 tcttgaccta agtggaaatt gccctcgttg ttataatgcc ccatttcctt gtgcgccgtg  
 901 taaaaataat tctcccctac agatccctgt aaatgctttt gatgcgctga cagaattaaa  
 961 agttttacgt ctacacagta actctcttca gcatgtgccc ccaagatggt ttaagaacat  
1021 caacaaactc caggaactgg atctgtccca aaacttcttg gccaaagaaa ttggggatgc  
1081 taaatttctg cattttctcc ccagcctcat ccaattggat ctgtctttca attttgaact  
1141 tcaggtctat cgtgcatcta tgaatctatc acaagcattt tcttcactga aaagcctgaa  
1201 aattctgcgg atcagaggat atgtctttaa agagttgaaa agctttaacc tctcgccatt  
1261 acataatctt caaaatcttg aagttcttga tcttggcact aactttataa aaattgctaa  
1321 cctcagcatg tttaaacaat ttaaaagact gaaagtcata gatctttcag tgaataaaat  
1381 atcaccttca ggagattcaa gtgaagttgg cttctgctca aatgccagaa cttctgtaga  
1441 aagttatgaa ccccaggtcc tggaacaatt acattatttc agatatgata agtatgcaag  
1501 gagttgcaga ttcaaaaaca aagaggcttc tttcatgtct gttaatgaaa gctgctacaa  
1561 gtatgggcag accttggatc taagtaaaaa tagtatattt tttgtcaagt cctctgattt  
1621 tcagcatctt tctttcctca aatgcctgaa tctgtcagga aatctcatta gccaaactct  
1681 taatggcagt gaattccaac ctttagcaga gctgagatat ttggacttct ccaacaaccg  
1741 gcttgattta ctccattcaa cagcatttga agagcttcac aaactggaag ttctggatat  
1801 aagcagtaat agccattatt ttcaatcaga aggaattact catatgctaa actttaccaa  
1861 gaacctaaag gttctgcaga aactgatgat gaacgacaat gacatctctt cctccaccag  
1921 caggaccatg gagagtgagt ctcttagaac tctggaattc agaggaaatc acttagatgt  
1981 tttatggaga gaaggtgata acagatactt acaattattc aagaatctgc taaaattaga  
2041 ggaattagac atctctaaaa attccctaag tttcttgcct tctggagttt ttgatggtat  
2101 gcctccaaat ctaaagaatc tctctttggc caaaaatggg ctcaaatctt tcagttggaa  
2161 gaaactccag tgtctaaaga acctggaaac tttggacctc agccacaacc aactgaccac  
2221 tgtccctgag agattatcca actgttccag aagcctcaag aatctgattc ttaagaataa  
2281 tcaaatcagg agtctgacga agtattttct acaagatgcc ttccagttgc gatatctgga  
2341 tctcagctca aataaaatcc agatgatcca aaagaccagc ttcccagaaa atgtcctcaa  
2401 caatctgaag atgttgcttt tgcatcataa tcggtttctg tgcacctgtg atgctgtgtg  
2461 gtttgtctgg tgggttaacc atacggaggt gactattcct tacctggcca cagatgtgac  
2521 ttgtgtgggg ccaggagcac acaagggcca aagtgtgatc tccctggatc tgtacacctg  
2581 tgagttagat ctgactaacc tgattctgtt ctcactttcc atatctgtat ctctctttct  
2641 catggtgatg atgacagcaa gtcacctcta tttctgggat gtgtggtata tttaccattt  
2701 ctgtaaggcc aagataaagg ggtatcagcg tctaatatca ccagactgtt gctatgatgc  
2761 ttttattgtg tatgacacta aagacccagc tgtgaccgag tgggttttgg ctgagctggt  
2821 ggccaaactg gaagacccaa gagagaaaca ttttaattta tgtctcgagg aaagggactg  
2881 gttaccaggg cagccagttc tggaaaacct ttcccagagc atacagctta gcaaaaagac  
2941 agtgtttgtg atgacagaca agtatgcaaa gactgaaaat tttaagatag cattttactt  
3001 gtcccatcag aggctcatgg atgaaaaagt tgatgtgatt atcttgatat ttcttgagaa  
3061 gccctttcag aagtccaagt tcctccagct ccggaaaagg ctctgtggga gttctgtcct  
3121 tgagtggcca acaaacccgc aagctcaccc atacttctgg cagtgtctaa agaacgccct  
3181 ggccacagac aatcatgtgg cctatagtca ggtgttcaag gaaacggtct agcccttctt  
3241 tgcaaaacac aactgcctag tttaccaagg agaggcctgg ctgtttaaat tgttttcata  
3301 tatatcacac caaaagcgtg ttttgaaatt cttcaagaaa tgagattgcc catatttcag  
3361 gggagccacc aacgtctgtc acaggagttg gaaagatggg gtttatataa tgcatcaagt  
3421 cttctttctt atctctctgt gtctctattt gcacttgagt ctctcacctc agctcctgta  
3481 aa 
// 




Table A.3: Examined TLR7 SNPs. 
 





LOCUS   NC_000023 (TLR8)  4306 bp    DNA linear   CON 03-MAR-2008 
DEFINITION  Homo sapiens chromosome X, reference assembly, complete sequence. 
ACCESSION   NC_000023 REGION: 12847029..12851334 
ORIGIN    
   1 cacctggcaa atactgctac tctaatactg tgcttccact tttgattttc cttaggaaaa  
  61 catgttcctt cagtcgtcaa tgctgacctg cattttcctg ctaatatctg gttcctgtga  
 121 gttatgcgcc gaagaaaatt tttctagaag ctatccttgt gatgagaaaa agcaaaatga  
 181 ctcagttatt gcagagtgca gcaatcgtcg actacaggaa gttccccaaa cggtgggcaa  
 241 atatgtgaca gaactagacc tgtctgataa tttcatcaca cacataacga atgaatcatt  
 301 tcaagggctg caaaatctca ctaaaataaa tctaaaccac aaccccaatg tacagcacca  
 361 gaacggaaat cccggtatac aatcaaatgg cttgaatatc acagacgggg cattcctcaa  
 421 cctaaaaaac ctaagggagt tactgcttga agacaaccag ttaccccaaa taccctctgg  
 481 tttgccagag tctttgacag aacttagtct aattcaaaac aatatataca acataactaa  
 541 agagggcatt tcaagactta taaacttgaa aaatctctat ttggcctgga actgctattt  
 601 taacaaagtt tgcgagaaaa ctaacataga agatggagta tttgaaacgc tgacaaattt  
 661 ggagttgcta tcactatctt tcaattctct ttcacacgtg ccacccaaac tgccaagctc  
 721 cctacgcaaa ctttttctga gcaacaccca gatcaaatac attagtgaag aagatttcaa  
 781 gggattgata aatttaacat tactagattt aagcgggaac tgtccgaggt gcttcaatgc  
 841 cccatttcca tgcgtgcctt gtgatggtgg tgcttcaatt aatatagatc gttttgcttt  
 901 tcaaaacttg acccaacttc gatacctaaa cctctctagc acttccctca ggaagattaa  
 961 tgctgcctgg tttaaaaata tgcctcatct gaaggtgctg gatcttgaat tcaactattt  
1021 agtgggagaa atagcctctg gggcattttt aacgatgctg ccccgcttag aaatacttga  
1081 cttgtctttt aactatataa aggggagtta tccacagcat attaatattt ccagaaactt  
1141 ctctaaactt ttgtctctac gggcattgca tttaagaggt tatgtgttcc aggaactcag  
1201 agaagatgat ttccagcccc tgatgcagct tccaaactta tcgactatca acttgggtat  
1261 taattttatt aagcaaatcg atttcaaact tttccaaaat ttctccaatc tggaaattat  
1321 ttacttgtca gaaaacagaa tatcaccgtt ggtaaaagat acccggcaga gttatgcaaa  
1381 tagttcctct tttcaacgtc atatccggaa acgacgctca acagattttg agtttgaccc  
1441 acattcgaac ttttatcatt tcacccgtcc tttaataaag ccacaatgtg ctgcttatgg  
1501 aaaagcctta gatttaagcc tcaacagtat tttcttcatt gggccaaacc aatttgaaaa  
1561 tcttcctgac attgcctgtt taaatctgtc tgcaaatagc aatgctcaag tgttaagtgg  
1621 aactgaattt tcagccattc ctcatgtcaa atatttggat ttgacaaaca atagactaga  
1681 ctttgataat gctagtgctc ttactgaatt gtccgacttg gaagttctag atctcagcta  
1741 taattcacac tatttcagaa tagcaggcgt aacacatcat ctagaattta ttcaaaattt  
1801 cacaaatcta aaagttttaa acttgagcca caacaacatt tatactttaa cagataagta  
1861 taacctggaa agcaagtccc tggtagaatt agttttcagt ggcaatcgcc ttgacatttt  
1921 gtggaatgat gatgacaaca ggtatatctc cattttcaaa ggtctcaaga atctgacacg  
1981 tctggattta tcccttaata ggctgaagca catcccaaat gaagcattcc ttaatttgcc  
2041 agcgagtctc actgaactac atataaatga taatatgtta aagtttttta actggacatt  
2101 actccagcag tttcctcgtc tcgagttgct tgacttacgt ggaaacaaac tactcttttt  
2161 aactgatagc ctatctgact ttacatcttc ccttcggaca ctgctgctga gtcataacag  
2221 gatttcccac ctaccctctg gctttctttc tgaagtcagt agtctgaagc acctcgattt  
2281 aagttccaat ctgctaaaaa caatcaacaa atccgcactt gaaactaaga ccaccaccaa  
2341 attatctatg ttggaactac acggaaaccc ctttgaatgc acctgtgaca ttggagattt  
2401 ccgaagatgg atggatgaac atctgaatgt caaaattccc agactggtag atgtcatttg  
2461 tgccagtcct ggggatcaaa gagggaagag tattgtgagt ctggagctaa caacttgtgt  
2521 ttcagatgtc actgcagtga tattattttt cttcacgttc tttatcacca ccatggttat  
2581 gttggctgcc ctggctcacc atttgtttta ctgggatgtt tggtttatat ataatgtgtg  
2641 tttagctaag gtaaaaggct acaggtctct ttccacatcc caaactttct atgatgctta  
2701 catttcttat gacaccaaag atgcctctgt tactgactgg gtgataaatg agctgcgcta  
2761 ccaccttgaa gagagccgag acaaaaacgt tctcctttgt ctagaggaga gggattggga  
2821 tccgggattg gccatcatcg acaacctcat gcagagcatc aaccaaagca agaaaacagt  
2881 atttgtttta accaaaaaat atgcaaaaag ctggaacttt aaaacagctt tttacttggc  
2941 tttgcagagg ctaatggatg agaacatgga tgtgattata tttatcctgc tggagccagt  
3001 gttacagcat tctcagtatt tgaggctacg gcagcggatc tgtaagagct ccatcctcca  
3061 gtggcctgac aacccgaagg cagaaggctt gttttggcaa actctgagaa atgtggtctt  
3121 gactgaaaat gattcacggt ataacaatat gtatgtcgat tccattaagc aatactaact  
3181 gacgttaagt catgatttcg cgccataata aagatgcaaa ggaatgacat ttctgtatta  
3241 gttatctatt gctatgtaac aaattatccc aaaacttagt ggtttaaaac aacacatttg  
3301 ctggcccaca gtttttgagg gtcaggagtc caggcccagc ataactgggt cctctgctca  
3361 gggtgtctca gaggctgcaa tgtaggtgtt caccagagac ataggcatca ctggggtcac  
3421 actcatgtgg ttgttttctg gattcaattc ctcctgggct attggccaaa ggctatactc  
3481 atgtaagcca tgcgagcctc tcccacaagg cagcttgctt catcagagct agcaaaaaag  
3541 agaggttgct agcaagatga agtcacaatc ttttgtaatc gaatcaaaaa agtgatatct  
3601 catcactttg gccatattct atttgttaga agtaaaccac aggtcccacc agctccatgg  
3661 gagtgaccac ctcagtccag ggaaaacagc tgaagaccaa gatggtgagc tctgattgct  
3721 tcagttggtc atcaactatt ttcccttgac tgctgtcctg ggatggcctg ctatcttgat  




3781 gatagattgt gaatatcagg aggcagggat cactgtggac catcttagca gttgacctaa  
3841 cacatcttct tttcaatatc taagaacttt tgccactgtg actaatggtc ctaatattaa  
3901 gctgttgttt atatttatca tatatctatg gctacatggt tatattatgc tgtggttgcg  
3961 ttcggtttta tttacagttg cttttacaaa tatttgctgt aacatttgac ttctaaggtt  
4021 tagatgccat ttaagaactg agatggatag cttttaaagc atcttttact tcttaccatt  
4081 ttttaaaagt atgcagctaa attcgaagct tttggtctat attgttaatt gccattgctg  
4141 taaatcttaa aatgaatgaa taaaaatgtt tcattttaca agaggagtgt atgataaata  
4201 tatcatagag aaattggtct ttaatataaa agaaattgcc atatacactg aattttttca  




Table A.4: Examined TLR8 SNPs. 
 
 





LOCUS   NC_000003 (TLR9) 3212 bp    DNA linear   CON 03-MAR-2008 
DEFINITION  Homo sapiens chromosome 3, reference assembly, complete sequence. 
ACCESSION   NC_000003 REGION: 52230221..52233432 
ORIGIN    
   1 gcagaggtga ggtgagtgtg gaggtggcac cgtgcaggat tccggctcac ggctattcgg  
  61 ccgtgggtcc ctggcagaag ttccggttat agaagtggtg gttgtccctg gtcagggcca  
 121 tgcccagctg ggcccagaag ctgcgctgac cactgggctg gtggggccag aggaggacac  
 181 tctggcggca gaggcgctgg cgcagccgca cgtagcggga gcggcggccg tcagggctca  
 241 ggatcaccag caccacgacg tccttgcggt cctccagcag gcgctgctgg gccagcagga  
 301 agctggcgcg caagagacca ctgacccggt ccgtgtgggc cagcacaaac agcgtcttgc  
 361 ggctgccata gaccgaggcc cacaggttct caaagagggt tttgccaggc agccagtcgc  
 421 gttcctccag gcacaggcgg agtgcccagc gcccacggca ctcctccagc tgcccccgaa  
 481 gctcgttgta cacccagtct gccactgcgc tctgcgtttt gtcgaagacc acgaaggcat  
 541 cgtagggcag ggcatcctca tctcgcccac tttgccgccc ccgccaggga agccaggcca  
 601 ggcacaggtg gaagcagtac cagaggtccc agccacagag gtgatgcagc atgggcacac  
 661 ccaggcccag agccacagcc agcagcgaga gggcgaaaca gtcccaggag agggcctcat  
 721 ccaggcagag gcgcaggtcc tgtgcaaaga tgctgaggcc ctggagctgg cccggactgc  
 781 cacacttcac ccggctgggc agaccgggca cggcagcctg cacctccagc aggaagtcca  
 841 taaaggccgc cccacaggcg cagtgcagag ggttggcgct tacatctagt atttgcaggg  
 901 cactcgccag gggcccaaac caggagtggt ccactgtctt gagggcgttg gcgctaaggt  
 961 tgagctctcg cagctccttg gccttggaaa agaagccggg ggccacgaag ctgatgctgt  
1021 tgcagctgac atccagcctc cggagccggg tgccagcagg caggctgcca ttggtcaggg  
1081 ccttcagctg gtttcctgcc aggtcgagga cttccagttt gggcaggaag tggaggctcc  
1141 accacttaaa gaaggccagg taattgtcac ggagacgcag cacctgtagg ctcttgggga  
1201 ggttgcgcag ggtttggggc aggagggtgt gcaggcggtt ctgggacaag tccagccaga  
1261 tcaaaccgct caggccttgg aagaagtgca gatagaggtc tccctcggcc cacatatggc  
1321 ccagtgcatt gccgctgaag tccagggccc gcagcgacgt actgcagagc tgctgggaca  
1381 cttggctgtg gatgttgttg tgggccaggc tgaggtggcg cagggtgcgc aggtgagcca  
1441 cgaagctgaa gttgtggccc acgccctgca tgccaaaggg ctggctgttg tagctgaggt  
1501 ccagggcctc cagtcgcggt agctccgtga atgagtgctc gtggtagagg tccagcttat  
1561 tgtgggacag gtctagcacc tgcagaccgg tcagcggcag gaactgggag ccattgactg  
1621 cctgcgagat gcagttgtgg ctcaggcgca ggcactgcag gtgcgagagc tgggcaaaca  
1681 tctccggctg cacggtcacc aggttgttcc gtgacagatc caaggtgaag ttgagggtgc  
1741 tgcagttggg cctgaagtct tcagagctgg gagtgtccac tggggccgga gcaaggtccc  
1801 caggctgcag ccagaccttc tcccctccat ctgcctcccc catggtggct gtcagctccg  
1861 aagctccgct gatgcggttg tccgacaggt ccacgtagcg caggccaggg aaggccctga  
1921 agatgccgag ctgggcctgg ttgatgaagt tcatctgcag acgcagagtc tggagcatgg  
1981 gcaggcgggc cagtggccgg agcgtggtct catcgagtga gcggaagaag atgccgtgca  
2041 tgtccagctc cttcagggcg accaggctcc cgaaggaagg ggccagagac aggtgggcaa  
2101 aggacaccct cttttggtaa ttgaaggaca ggttaagctt gcgcagctgt gttaggccct  
2161 ggaaggcctt ggttttagtg atgcatttgt agaggaagtt ctcactcagg tccagcactc  
2221 ggaggtttcc cagcccacgg aaccaactgg cattcagcca ggagagagaa ctgtccttca  
2281 acaccaggcc ttcaagacgg ctcaggtggc tgaaggtatc gggatgtagc tgggggaagt  
2341 gacgagggca ctccatgcag gggttgggag cgtggtcgca gcggcggcaa tttccgccca  
2401 catcgagcac acgcagggcg gtcagattgg ccaggtcctc aggcgccagt ttgacgatgc  
2461 ggttgtagga caacagcaga tactccaggc tggaaggcag gttgcggggc accacagtga  
2521 ggttgttgta cttgagtgac aggtgggtga ggttgcccag gccaaggagg gcacccgggg  
2581 ccacctccag tgcctgcctg caggggttct tgtaataaca gttgccgtcc atgaatagga  
2641 agcgcagggc atgcaggccg gcgaggctgg cagagtctag catcaggatg ttggtatggc  
2701 tgagggacag ggatatgagg gatttgggca gcgcaggcac agtcatgatg ttgttgtagc  
2761 tcaggtttag ctcttccagg gtgggcacag ccaagaaggt gctgggctcg atggtcatgt  
2821 ggcaggggaa gtgcatgggg ctgaggccaa ccggcgggca gttccacttg aggttgagat  
2881 gccgcaggct gggcaggtgg gcaaagtcag aatcatggag gtggtggatg cggttggagg  
2941 acaaggaaag gctggtgaca ttgccacggg gtgctgccat ggagaagtgg ggcacagact  
3001 tcaggaacag ccagttgcag ttcaccaggc cgtggggctg gagctcacag ggtaggaagg  
3061 caggcaaggt acccagggcc agggtcatgg ccagcatgat ggcctgcacc aggagagaca  
3121 gcgggtgcag ggcgctgcgg cagaaaccct gtgggggtgg gagggctgtg tgagtggccg  
3181 gcccccagct ctacctccac ccactccact tc 
// 




Table A.5: Examined TLR9 SNPs. 
 
 
